Contents

• Andrey Kotzev, Margarita Kamenova
  Etiology and pathogenesis of gastric cancer 4

• Jivka Ivanova, Mihail Boyanov, Andon Toshev
  Association of the FokI and BsmI Polymorphisms of the Vitamin D Receptor Gene with the Bone Mineral Density in Postmenopausal Bulgarian Women 12

• Nadejda Madjirova, Stoyanka Velkova
  Circadian rhythm of temperature and pulse of Moclobemid, Venlafaxine, Fluoxamine and Citalopram 22

• Todor Stoev
  Psychological Influences Under Stress – Strategy for Prevention and Control 34

• Valeria Tananska
  Medicine – basics and relevant issues 39

• Svetlin Tsonev, Temenuga Donova, Maria Milanova
  Women with Cardiac Syndrome X- Depressive Symptoms and a Possibility to be Assessed 44

• R. Dimova, B. Marinov, A. Nachev, A. Tomova, Ph. Kumanov
  Mayer-Rokitansky-Küster-Hauser syndrome. A case report with brief review of the literature 50

• Chronicle 56

• Author’s guidelines 61

Съдържание

• Андрей Коцев, Маргарита Каменова
  Етиология и патогенеза на стомашния рак 4

• Живка Иванова, Михаил Боянов, Андон Тошев
  Връзка между полиморфизмите FokI и BsmI на витамин D рецепторния ген и костната минерална плътност на постменопаузални българки 12

• Надежда Маджирова, Стоянка Велкова
  Циркационален ритъм на температурата и пулса при лечение с Моклобемид, Венлафаксин, Флуоксамин и Циталопрам 22

• Тодор Стоев
  Психически въздействия при стрес – стратегия за превенция и управление 34

• Валерия Тананска
  Медицина: основа и съответни проблеми 39

• Светлин Цонев, Теменуга Донова, Мария Миланова
  Жени с Кардиологичен синдром Х- депресивни симптоми и възможност за оценката им 44

• Р. Димова, Б. Marinov, А. Начев, А. Томова, Ф. Куманов
  Синдром на Mayer-Rokitansky-Küster-Hauser: описание на случай с кратък обзор на литературама 50

• Хроника 56

• Указания за авторите 61
**Etiology and Pathogenesis of Gastric Cancer**

Andrey Kotzev¹, Margarita Kamenova²

¹Clinic of Gastroenterology, University Hospital „Alexandrovsk“a, Sofia
²Department of Clinical Pathology, Pirogov University Hospital, Sofia

---

**Abstract**

Gastric cancer is neoplasm with poor prognosis and high mortality rates. Gastric cancer is the third most prevalent cancer worldwide. There are a lot of studies, but the etiology and pathogenesis of gastric cancer are not yet fully understood. Diet, *H. pylori* infection, inflammation and genetic polymorphism play basic role in the gastric pathogenesis. Gastric carcinogenesis is a multistep and multifactorial process involving genetic end epigenetic disturbances, altered expression of numerous cytokines, proto-oncogenes, tumor-suppressor genes, cell-adhesion molecules and cell-cycle regulators. The lost balance between cell proliferation and cell apoptosis is a key event in initiating stages of gastric carcinogenesis. The influence of the external factors upon the different and complex molecular gastric cancer pathways must be investigated in order to reveal completely the biology of gastric cancer.

---

**Етиология и патогенеза на стомашния рак**

Андрей Коцев¹, Маргарита Каменова²

¹Клиника по гастроентерология, УМБАЛ „Александровска“, София
²Отделение по клинична патология, МБАЛСМ „Пирогов“, София

---

**Резюме**

Стомашният рак е неоплазия с неблагоприятна прогноза и висока смъртност. Стомашният рак е на трето място по честота в света сред малигнените заболявания. Етиологията и патогенезата на стомашния карцином са обект на много проучвания, но все още не са напълно изяснени. Хранителните фактори, инфекциията с *H. pylori*, възпалението и генетичния полиморфизм изгражат основна роля в стомашната патогенеза. Патогенезата на стомашния рак при човека е многоетапен процес, който е свързан с генетични и епигенетични нарушения, с променена експресия на многоциклонини цитокини, прото-онкогени, тумор-супресорни гени, клетъчни адхезионни молекули и регулатори на клетъчен цикъл. Изгубеното равновесие между клетъчната пролиферация и апоптоза е ключов момент в инцирирането на стомашната карциогенеза. За по-пълното разкриване на
Gastric cancer is the third most common cancer worldwide and has very poor prognosis. Although the incidence of gastric cancer is declining, this aggressive disease is still the second cause of cancer mortality. The incidence of gastric cancer varies geographically, with highest rates in Japan, China, Eastern Asia, Eastern Europe, Central and South America, while North America, Western Europe, Australia and parts of Africa are considered as low-risk areas (29). Adenocarcinoma of the stomach comprises 90-95% of all stomach malignancies and histologically is classified as intestinal or diffuse subtype (33). Intestinal subtype is usually sporadic well differentiated cancer and occurs in endemic areas, whereas diffuse subtype is predominantly poorly differentiated or undifferentiated, and much rarer. In recent years, the incidence of the cardia and gastroesophageal junction cancers is steadily increasing (15). Atrophic gastritis, gastric adenomas and subtotal gastrectomy are pre-malignant conditions for developing of the gastric cancer. Patients with familial adenomatous polyposis (FAP), hereditary non-polyposis colon cancer (HNPCC), and Peutz-Jeghers syndrome are at elevated risk of gastric cancer.

**Key words:**
gastric cancer, carcinogenesis, *H. pylori*, inflammation, apoptosis, proliferation

**Introduction**

The pathogenesis of gastric cancer is a multifactorial process, which is still not fully elucidated. Environmental factors and genetic abnormalities promote the gastric carcinogenesis. The intestinal subtype of cancer is characterized with a multistep progression through chronic atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately to cancer. In contrast, diffuse subtype of gastric cancer does not follow such a consecutive pattern and no known precursor lesion is found. The most important exogenous risk factors for gastric cancer are infection with *H. pylori* and diet.

**H. pylori and gastric cancer**

*H. pylori* infection is the primary cause for gastric carcinogenesis. *H. pylori* has been labeled as a group I carcinogen for the development of noncardia gastric cancer by the International Agency for Research on Cancer (IARC) in 1994 (2). Epidemiological data and animal studies demonstrate that *H. pylori* infection is strongly associated with gastric cancer. The incidence of gastric cancer is high in countries with high incidence of *H. pylori* infection, and this increases the risk for developing gastric cancer two- to eightfold (30). The development of atrophic gastritis is a key event in the initiation of the gastric cancer, and regression of gastric atrophy and intestinal metaplasia is reported as a result of eradication of *H. pylori* (12). In most infected patients, *H. pylori* causes a mild pangastritis, but some people develop predominantly antral or corpus gastritis. Host acid output is associated with the topographical distribution of *H. pylori* invasion. The individuals with low acid output are predisposed to develop multifocal atrophic
gastritis and have a higher risk for gastric cancer than people with high acid output in whom *H. pylori* colonization and inflammation are restricted to the antrum. The mechanisms of tissue damage elicited by *H. pylori* include release of cytotoxins, phospholipase, toxic ammonia, pro-inflammatory cytokines and reactive oxygen species (ROS) in the gastric epithelium (24). ROS could injure the genomic DNA and promote the cancer carcinogenesis. Consequences of *H. pylori* infection are also elevated gastrin levels, downregulated vitamin C levels and achlorhydria, which are additionally prerequisites for the development of gastric cancer (46). It seems that the inflammatory answer started by *H. pylori* is more harmful to the host than the bacteria.

*H. pylori* plays a dual role for sustenance of the equilibrium between apoptosis and proliferation in gastric mucosa. Initially, *H. pylori* infection increases apoptosis directly or indirectly by inducing the expression of Bak, Fas receptor (CD95), CD95L, INF-γ, IL-1β, TNF-α, TNF-α receptors, cytochrome c and TGF-β, and induces atrophy. Nevertheless, this event is transitory and enhanced cell turnover occurs as a compensatory reaction, probably combined with lessened apoptosis. Induction of proinflammatory cytokine macrophage migration inhibitory factor (MIF) by *H. pylori* infection leads to increased Bcl-2 expression, and downregulation of p53 and apoptosis (6). A study found that *H. pylori* directly promotes gastric carcinogenesis by diminishing the expression of E-cadherin, but recent data challenge this finding (44, 5). Finally, if hyperproliferative state of the gastric cells remains permanent, malignant process could be triggered. Therefore, it could be presumed that *H. pylori* infection stimulates cell cycle progression and could lead to disturbed balance between apoptosis and proliferation in the pathogenesis of gastric cancer.

Virulence factors are very important for the oncogenic role of *H. pylori*. Cytotoxin-associated gene-A (CagA) is the main virulence factor of *H. pylori*. CagA is injected in the gastric epithelial cells by the type IV secretory system followed by tyrosine phosphorylation and activation of the cytoplasmic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). The complex CagA-SHP2 stimulates cell turnover, migration and adhesion. CagA induces the expression of nuclear factor κB (NF-κB), which produces the proinflammatory cytokine IL-8 (23). NF-κB serves as a key mediator in promoting and sustaining the unrestrained cell proliferation in the history of *H. pylori*-associated gastritis. Toll-like receptors (TLRs) identify pathogen-associated molecular patterns and play a crucial role in the initial innate immune response to *H. pylori* infection. TLRs are activated by multiple parts of the bacterium, including CagA, followed by induction of inflammatory signaling pathways and expression of NF-κB, mitogen-activated protein kinase (MAPK), IL1, IL8, TNF-α, iNOS, COX-2, vascular endothelial growth factor (VEGF), chemokins, matrix metalloproteinases and adhesion molecules (48) (Fig. 1). CagA promote and cell motility by the activation of the HGF/scatter factor receptor c-Met (11). p53 tumor suppressor pathway is suppressed in patients with CagA-positive *H. pylori* strains and these patients have higher risk of gastric cancer compared with patient with CagA-negative strains (8). Vacuolating cytotoxin (VacA) is another virulence factor of *H. pylori*, which acts like an anion channel. The precise role of VacA in gastric carcinogenesis is obscure, but strains with sl/ml allele are connected with increased risk of gastric cancer (13).

### Diet and gastric cancer

The role of diet in gastric cancer has been investigated in many epidemiological studies. Most of these studies reveal that high consumption of salt, red and processed meat, refined carbohydrates, salted food, pickled or smoked foods and saturated fat is connected with elevated risk of gastric cancer (1, 20). Contradictory results are available from the studies investigating the impact of the presumable protective diet on gastric cancer. Evidence for the protective role of fresh vegetables and fruits, as well as fiber rich cereals, whole grain, green tea, and micronutrients (vit. A, vit. B6, vit. C, vit. E, carotenoids, flavonoids, selenium, zinc) intake exists, but the outcome of some studies question these data (1, 25). The role of cigarette
smoking and alcohol intake in pathogenesis of gastric cancer is disputable, but recent data demonstrated their significance as risk factors (36). Acetaldehyde exposure, associated with cigarette smoking and alcohol consumption, is accepted as a local carcinogen and risk factor of gastric cancer (41). Consumption of dietary nitrosamines also increases the risk of stomach cancer (32).

**Host genetic polymorphism and gastric cancer**

Genetic polymorphism of the host plays a significant role for the development of gastric cancer. Polymorphism of the genes that code pro-inflammatory cytokines could influence the extent of inflammatory response to *H. pylori* infection. IL-1β is a powerful pro-inflammatory cytokine and acid inhibitor. IL-1β -511T and TNF-α -308A carriers are at increased risk of gastric cancer, although some ethnic differences exist (18). Genetic polymorphism of metabolic enzymes defines the individual differences in ability to detoxify chemical carcinogens. CYP2E1 is a cytochrome P450 isoenzyme which participates in metabolism of carcinogens and catalyzes the activation of different nitrosamines. CYP2E1 C2 Asian carriers are at elevated risk of developing gastric cancer (7). GSTM1 is a major part of the glutathione S-transferase (GST) superfamily and evidence exists that

**Figure 1.** Mechanism of action of *H. pylori* in the gastric epithelium. ICAM= Inter-cellular adhesion molecule-1; MMP-9=Matrix metalloproteinase-9; iNOS=inducible nitric oxide synthase; SHP2= Src homology-2 domain containing protein tyrosine phosphatase-2. AP-1=Activating protein-1.
Host immune response and gastric cancer

Host T cell immunity is crucial for the pathogenesis of *H. pylori* infection. The progression to gastric atrophy and cancer in patients with *H. pylori* infection is dependent on a Th1 (pro-inflammatory) immune response (3). Intracellular pathogens, including bacteria, induce Th1 responses, whereas extracellular pathogens like helminthic parasites provoke polarized Th2 responses. A recent study found that *S. japonicum* co-infection with *H. pylori* is associated with alterations in IgG responses to *H. pylori* and less gastric atrophy (17). Possible reason is that concurrent helminthic infection downregulates the acute proinflammatory Th1 immune response. Lintestinal helminthiasis is widespread in people in developing countries, and therefore predominantly Th2 response to infection with *H. pylori* is observed, whereas people in developed countries mount predominantly Th1 response.

These data could explain and the so called „African enigma“, characterized with high rates of *H. pylori* infection is some parts of Africa, but with low incidence of gastric cancer.

Molecular biology of gastric cancer

The considerable advance in the knowledge of the molecular basis of human cancer improve the understanding of multiple molecular alterations in the gastric cancer. The pathogenesis of gastric cancer is connected with genetic and epigenetic abnormalities. Disturbed balance between cell proliferation and apoptosis is a hallmark of stomach cancer, which is associated with overexpression of growth factors and protooncogenes, and enhanced suppression of proapoptotic pathways. Amplification of the EGF receptor type II (c-erbB-2/neu) is documented in intestinal-type gastric cancers, but is rarely seen in diffuse type (40). In contrast, K-sam oncogene, a member of the fibroblast growth factor receptor family, is expressed predominantly in diffuse type of gastric cancer, and K-sam positive patients have unfavorable prognosis (45). C-met oncogene which encodes a tyrosine kinase receptor for hepatocyte growth factor is also overexpressed mainly in diffuse gastric cancers and associated with poor survival (16). Overexpression of the C-myc oncogene has been reported in over 40% of gastric cancers and is found in early-onset gastric cancers (45). BMI1 which is a key protein in the Polycomb group (PcG) proteins, acts as an oncogene in gastric cancer and BMI1 overexpression is correlated with advanced clinical stage and lymph node metastasis (50). Signal transducers and activators of transcription (STAT) act as signal transducers in the cytoplasm and as transcription factors in the nucleus, and STAT3 expression in gastric cancer indicates poor prognosis (14). The expression of anti-apoptotic protein Bcl-2 is increased in gastric dysplasia as well as carcinoma (9). The expression of the proliferative marker Ki-67 is also elevated in gastric cancer, and is correlated with higher rate of metastatic lymph nodes and advanced disease (47). Telomerase reactivation is a common event in gastric adenocarcinoma, but it is not related to histopathological parameters (22). Expression of the cell surface receptor CD44v6 and matrix metalloproteinase-7 (MMP)-7, and VEGF-D in gastric cancer is correlated with distant metastatic disease (38, 42).

Inactivation of tumor suppressor genes and proteins is an inherent feature of the stomach carcinogenesis. p53 is the most frequently mutated tumor suppressor gene in gastric carcinogenesis. Overexpression of p53 protein is associated with poor survival, aggressive pathologic features and could be used as a predictive
biomarker for developing and recurrence of gastric cancer (27). Aberrant methylation of the tumor suppressor and cell-cycle regulator p16 is observed frequently in lymphatic-invasive gastric carcinomas (21). The loss of expression of pRb is correlated with poor outcome, whereas p21 expression is associated with favorable prognosis in patients with gastric cancer (31). Reduced expression of cyclin-dependent inhibitor p27 is detected in nearly 50% of gastric cancers (39). Runt-related transcription factor 3 (RUNX3) acts like a tumor suppressor of gastric cancer and is implicated in gastric carcinogenesis. RUNX3 expression is reduced or lost in 60% of the primary gastric cancers and loss of the RUNX3 is detected in nearly 90% of advanced gastric cancers (34). The frequency of RUNX3 methylation is significantly increased in patients with advanced gastric lesions and could be used as an independent prognostic factor and a possible therapeutic target for gastric cancer (10). Suppression of proapoptotic Bax protein is an early molecular event during gastric carcinogenesis (9). Tumor hypoxia is an indispensable attribute for the development of gastric cancer. Increased expression of hypoxia-inducible factor (HIF)-1α is reported in carcinogenesis of stomach cancer, and HIF-1α and p53 positive tumors are often presented with undifferentiated type and infiltrative growth pattern (43). Inactivation of E-cadherin by mutation and hypermethylation is found predominantly in cases with diffuse gastric cancer, whereas E-cadherin mutation is rarely found in intestinal type. Germ-line mutations in E-cadherin (CDH1) are associated with loss of E-cadherin function and the familial form of diffuse gastric cancer, hereditary diffuse gastric cancer (4). Patients with abnormal expression of E-cadherin and positive expression of MUC1 have unfavorable prognosis (37).

Chromosomal abnormalities and loss of heterozygosity (LOH) are considered nonspecific in the development of both subtypes of gastric adenocarcinoma. Gastric cancers with high-level microsatellite instability (MSI-H) are characterized by antral location, intestinal type of cancer and have better prognosis (19). In contrast, a recent study found that mitochondrial microsatellite instability (mtMSI) in gastric dysplasia is associated with poor prognosis (28).

The role of stem cells in oncology has been extensively investigated during the last years. A study found that stem cells of bone marrow origin migrated and proliferated in the mouse stomach epithelium after Helicobacter infection. After 20 weeks these marrow-derived cells differentiated in gastric epithelial cells, and finally by 52 weeks early gastric cancer occurred (26). These data support the putative role of the stem cells in the pathogenesis of gastric cancer, but more studies are needed this hypothesis to be validated.

Although the great progression in elucidation of the molecular biology of gastric cancer, the pathogenesis of gastric cancer still remains unknown. It is difficult to be determined with certainty which of the changed signaling pathways is characteristic only of gastric cancer. It is still impossible also to separate the causal molecular alterations from the incidental ones and from those which are simply result of the tumor development. Gene-environment interaction is of extreme importance in pathogenesis of gastric cancer. Hence, future studies must explore not only the genetic aberrations in this lethal disease, but also the influence of exogenous risk factors (H. pylori, diet, lifestyle) upon intimate molecular mechanism in carcinogenesis of gastric cancer.

References

1. Коцев, И., М. Стамболийска, И. Шалев и сътр. Рискови и протективни фактори за стомашни полипи и стомашен рак. Съвременна медицина, 2, 2007, 33-41.


References


35. **Milne, A.N., R. Carvalho, F.M. Morsink et al.** Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. *Mod. Pathol.*, 19(4), 2006, 564-572.


---

**Address for correspondence:**

**Andrey Kotzev, MD, PhD**

Clinic of Gastroenterology, University Hospital „Alexandrovska“, Sofia

**Andрей Коцев,**

Клиника по гастроентерология, УМБАЛ „Александровска“, София
Numerous studies on vitamin D receptor (VDR) gene polymorphisms differ with conflicting data in various populations. The aim if this research project was to study the association of the FokI and BsmI polymorphisms of the vitamin D receptor (VDR) gene with the bone mineral density (BMD) in postmenopausal Bulgarian women.

**Methods:** 400 women referred for bone densitometry participated. BMD was measured by X-ray absorptiometry (on a DTX-100 device, Osteometer Meditech USA, and on a QDR 4500.
A device, Hologic Inc., Bedford, USA. The genetic analysis was performed on lymphocytes from whole blood.

**Results:** The calculated relative risk (RR) for low bone mineral density is higher in the presence of the FokI marker (3.67) compared to the BsmI marker (2.30). The association between the investigated polymorphisms and low BMD on a population level was expressed by the etiological factor: EF=0.55 for the FokI marker and EF=0.45 for the BsmI marker. We concluded that the FokI and BsmI polymorphisms were closely related to low BMD at the forearm, lumbar spine and femoral neck. Further studies of larger cohorts and in ethnically diverse subgroups are necessary to assess the role of both polymorphisms as genetic markers determining osteoporosis risk.

**Key words:**
osteoporosis; vitamin D receptor; bone mineral density; polymorphisms; FokI and BsmI

---

**Introduction**

Bone mineral density (BMD) is a major determinant of fracture risk and has an important genetic background. The first gene suspected to determine BMD was the vitamin D receptor (VDR) gene (15,17). It is localized on chromosome 12q13-14 in a region that contains other genes of interest to bone molecular biology - the collagen type2α1 (COL2A1) and the 1α-hydroxylase genes (2,14). The VDR gene has at least 11 exons and spans 60 kb (10, 18). Several polymorphic variants described so far include a cluster of linked sites near or in exon IX (BsmI, ApaI, TaqI and Long/Short polyA track) and a FokI site in exon II, containing the initiation codon (10).

In 1992 Morrison et al. found an association between bone turnover and several polymorphisms at the 3'-end of the VDR gene defined by the restriction enzymes BsmI, Apal, and Taql (16). Two years later they reported a close association between VDR-BsmI genotype BB and low BMD in a twin study (15).

In 1996 another locus of the VDR gene was associated with BMD. Gross et al. identified an initiation start codon polymorphism at the 5'-end of the VDR gene associated with an individual's risk for osteoporosis (8). These polymorphisms defined by the restriction enzyme FokI showed a translation product of VDR with a difference in length of three amino acids depending on the allelic variants (7).

Since the initial data for an association of these VDR polymorphisms with BMD, studies on different populations have showed controversial conclusions and some investigators have
found an association of these polymorphisms with BMD (7,8,12,13,15,16) while others have not (6).

The human VDR DNA presents two potential translation initiation (ATG) codons in exon II (8). A T/C polymorphism (ATG to ACG) has been shown at the first ATG which is referred as a start codon polymorphism (SCP). Initiation of translation from the second AUG shortens the VDR by three amino acids (1). Such a difference might contribute to altered receptor function in contrast to the silent polymorphism in intron VIII and exon IX. In the study of Aria et al. the shorter form of the VDR showed 1.7-fold greater transcriptional activation in HeLa cells than the longer form (1). The restriction endonuclease FokI can detect the SCP (7-9). VDR alleles with the first ATG are described by f (the longer form of 427aa, named M1) and VDR alleles without the first ATG are described by F (the shorter form of 424aa, named M4). The shorter form F or M4 is present in 65% of VDR alleles in humans.

The aim of this study was to examine the association of these VDR gene polymorphisms with BMD in a random population sample of Bulgarian menopausal women. This work is the final report of a study, whose preliminary results were published elsewhere (11).

Materials and Methods

Subjects

400 unrelated menopausal Bulgarian women were recruited for the study. Diseases and medications known to affect bone metabolism were used as exclusion criteria. All subjects were grouped according to their BMD. 220 participants had low bone density (and were referred to as cases) and 180 had normal BMD (and were used as controls). The age of the participants ranged between 36-56 yrs among the cases and between 34-58 years in controls respectively. All participants gave their informed consent. This work has been approved by the responsible authorities at the Alexandrovska Hospital.

Bone densitometry

BMD was measured at the distal forearm by single-energy X-ray absorptiometry (SXA) on a DTX-100 Unit (Osteometer Meditech, USA) and at the lumbar spine (L1-L4) by dual-energy X-ray absorptiometry (DXA) on a Hologic QDR 4500 A device (Hologic Inc., Bedford, MA, USA).

On the DTX-100 the distal region of interest begins at the 8 mm separation point between radius and ulna and then continues proximally for a distance of 24 mm. The ultra-distal site extends from the radial endplate proximally to the 8 mm point. The manufacturer’s Danish database was used (issued 1994). BMD of the lumbar spine and femoral neck in the posterior-anterior (PA) projection was measured on a Hologic QDR 4500 A densitometer; with software version 8.26:3 (Hologic, Inc., Bedford, USA). The manufacturer’s American reference database was used (issued 1991) (42).

Genotyping

DNA was isolated from whole blood. Primers and PCR conditions for amplifying exon 2 of the VDR gene were designed accordingly to Gross et al. (18). The region of genomic DNA containing the BsmI polymorphic site in intron 8 was amplified as described by Ingles et al. (6).

dATP, dCTP, dTTP, dGTP – 1,25 mM each were used to amplify exon 2 and intron 8 with Taq DNA Polymerase. 100 ng of the DNA were used as template in the PCR reactions.

Primers (2a and 2b) flanking exon II were used to amplify a 265 bp PCR product that is then digested with FokI. Digestion of the PCR product with FokI generates two fragments of 196 bp and 69 bp. Individuals homozygous for the FF genotype have a single uncut 265 bp fragment, while homozygous for the ff genotype have two fragments of 196 bp and 69 bp. The heterozygotes Ff have all three bands.

The polymorphic region was located in intron VIII at 280 bp from the 5’ start of the intron without amino acid change but disappearance of the restriction site for BsmI. BsmI
cuts the b allele of the VDR gene but not the B allele. The primers (U and L) were used to amplify 821 bp PCR product which was then digested with Bsm1. Digestion of the PCR product with Bsm1 generates two fragments of 650 bp and 175 bp. Individuals homozygous for the BB genotype have a single uncut 821 bp fragment, while homozygous for the bb genotype have two fragments of 650 bp and 175 bp. The heterozygotes Bb have all three bands.

PCR products were digested with FokI and Bsm1 for 4h and electrophoresed through a 2% agarose gel. Individuals were scored as FF, Ff, ff and BB, Bb, bb according to the digestion pattern.

### Statistical analysis

The relative risk (RR) was defined as:

$$RR = \frac{a \times d}{b \times c}$$

where:

- **a** is the number of carriers among the cases
- **b** is the number of not carriers among the cases
- **c** is the number of carriers among the controls
- **d** is the number of not carriers among the controls

The etiological factor (EF) was defined as:

$$EF = \frac{RR - 1}{RR} = \frac{a}{a + b}$$

The EF shows what part of the disease might be attributable to the studied polymorphisms on a population level.

Data were evaluated by \( \chi^2 \)-test and presented as means ± SD

### Results

#### The FokI marker

The distribution of genotypes and alleles by FokI in the subgroups of cases and controls is shown in Table 1. The genotype frequencies found in our preliminary report were 0,25 for FF, 0,43 for Ff, 0,32 for ff in cases and 0,52 for FF, 0,45 for Ff, 0,03 for ff in controls. The allelic frequencies were 0,47 (F), 0,53 (f) in cases and 0,75 (F), 0,25 (f) in controls (43). Allelic and genotype frequencies were calculated in cases (with low BMD and/or osteoporosis) and in controls (normal BMD), and in the homo- and heterozygotes (see Table 1). The results are statistically significant after \( \chi^2 \)-test (p<0,05).

When compared with genotype frequencies in cases with low BMD and in controls more common is ff in cases (28%) than in controls (6%). Less common in cases are found FF (25%) compared with controls (54%). The frequency of heterozygotes is higher in cases (48%) than in controls (40%). The statistical significance of these results was defined after a \( \chi^2 \)-test (Table 1). P was <0,05.

The correlation between the FokI genotype and BMD at the forearm site is shown in Fig. 1. Higher BMD was found in FF individuals and lower in ff individuals. The correlation remained unchanged when introducing BMD values (T-score) (see Fig. 1).

The relationship between the different genotypes FokI and BMD at the lumbar spine and femoral neck is shown in Fig. 2.

#### The Bsm1 marker

The distribution of genotypes and alleles by Bsm1 in the subgroups of cases and controls is shown in Table 2. The genotype frequencies found in our preliminary report were 0,33 for BB, 0,38 for Bb, 0,29 for bb in cases and 0,06 for BB, 0,44 for Bb, 0,50 for bb in controls. The allelic frequencies were 0,52 (B), 0,48 (b) in cases and 0,28 (B), 0,72 (b) in controls (43). Allelic and genotype frequencies by Bsm1 as defined incases (with low BMD and/or osteoporosis) and in controls, and in the homo- and heterozygotes, are presented in Table 2. The results were statistically significant – the \( \chi^2 \)-test (p<0,05).

The BB genotype was more common in cases with low BMD and/or osteoporosis (35%) vs. 11% in controls with normal BMD and inversely the bb genotype was less common in cases (2%) than in controls (38%) (Table 2). The
heterozygotes Bb were more common in controls (51%) compared with cases (45%). Statistical significance of these results as defined from $\chi^2$-test was within the limits ($p<0.05$).

The correlation between the genotype and BMD at the forearm is shown in Fig. 3. The relationship between these genotypes and the lumbar spine and femoral neck BMD is shown in Fig. 4.

The published frequencies for both alleles under study are presented for visual comparison in Figs. 5 and 6.

The relative risk (RR) for low BMD and/or osteoporosis in the presence or absence of a given marker was as follows:

For the FokI marker – RR=3.67

and for the BsmI marker – RR=2.30

The EF showing what part of the illness is attributable to the associated factor on a population level was as follows:

For the FokI marker EF=0.55 and for the BsmI marker EF=0.45

The EF for both markers shows that a more substantial part of the illness is associated with the FokI (55%) than with the BsmI (45%). This suggests that the FokI marker might be more informative.
**Discussion**

The VDR gene is known as a candidate gene determining a part of the genetic basis of osteoporosis (3-5,19,20). While the other studied polymorphisms do not alter the sequence of the VDR protein, the FokI polymorphism encodes alternate proteins that differ in length by three amino acids (5,9). That probably influences the function of VDR and contributes to the differences in BMD. The BsmI intronic polymorphism could be relevant for translational differences of the VDR (a “functional polymorphism” which is rather unlikely) or might act in strong linkage disequilibrium with a putative functional one in the VDR or a nearby gene.

The observed allelic frequencies in controls and cases were compared with published allelic frequencies in European populations (4,19) as follows: 60-69% for F allele and 31-40% for f allele, 37-45% for B allele and 52-67% for b allele; and with published allelic frequencies in Asian populations (32,34): 62% for F allele and 38% for f allele, and 5-12% for B allele and 88-95% for b allele respectively, normative for menopausal women (see Fig. 5 and Fig. 6).

**Table 2.** Distribution of genotypes and alleles by BsmI

<table>
<thead>
<tr>
<th>Genotype</th>
<th>cases</th>
<th>controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>BB</td>
<td>Bb</td>
</tr>
<tr>
<td>Frequency</td>
<td>76</td>
<td>98</td>
</tr>
<tr>
<td>H0</td>
<td>0,35</td>
<td>0,45</td>
</tr>
<tr>
<td>χ² / p</td>
<td>33,44</td>
<td>p&lt;0,05, df=2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genotype</th>
<th>number</th>
<th>frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>BB</td>
<td>20</td>
<td>0,11</td>
</tr>
<tr>
<td>Bb</td>
<td>92</td>
<td>0,51</td>
</tr>
<tr>
<td>bb</td>
<td>68</td>
<td>0,38</td>
</tr>
</tbody>
</table>

**Figure 2.**

BMD (in g/cm²) of the lumbar spine (L1-L4) and femoral neck for the different genotypes by FokI. Data are shown as means ±1SD.

*p=0,02 for FF vs. Ff, *p=0,03 for FF vs. ff at the Lumbar spine p>0,05 for FF vs. Ff, p>0,05 for FF vs. ff at the Femoral neck

![BMD graph](attachment:image.png)
The genotype frequencies of controls (N=180) from this study are 54% for FF, 40% for Ff and 6% for ff. In comparison they were 52% for FF, 45% for Ff and 3% for ff in the preliminary study in controls. The genotype frequencies of cases (N=220) are 25% for FF, 48% for Ff and 28% for ff (see Table 1). In comparison they were 25% for FF, 43% for Ff and 32% for ff in the preliminary study (43). The compared groups of Bulgarian and European and Asian populations differ by distribution of allelic frequencies. We compared these frequencies with published genotype frequencies for European populations (4,19): 28-48% for FF, 41-58% for Ff and 6-16% for ff and with genotype frequencies for Asian populations (1): 36-37% for FF, 49-51% for Ff and 12-15% for ff (defined in menopausal women). Current allelic frequencies do not differ.
from frequencies in our preliminary report (48 vs. 47% for F, 52 vs. 53% for f in cases and 74 vs. 75% for F, 26 vs. 25% for f in controls). Our data also do not significantly differ from data published by Gross et al. regarding the association of the genotype with low BMD (8). In their group (N=100) genotype frequencies differed from that of our group and were 37% for FF, 48% for Ff and 15% for ff and the differences are most significant for ff (8).

The genotype frequencies of controls (N=180) from this study are 11% for BB, 51% for Bb and 38% for bb. In comparison they were 6% for BB, 44% for Bb and 50% for bb in the preliminary study. The genotype frequencies of cases (N=220) are 35% for BB, 45% for Bb and 21% for bb (Table 2). In comparison they were 33% for BB, 38% for Bb and 29% for bb in the preliminary study. The observed allelic frequencies in our study population did not differ significantly from data in European populations (4,19) and data in our preliminary report (57 vs. 52% for B, 43 vs. 48% for b in cases and 37 vs. 28% for B, 63 vs. 72% for b in controls). Comparing Bulgarian and Asiatic population the differences were significant (1). The frequencies were compared with published genotype frequencies for European populations (4,19): 12-25% for BB, 39-72% for Bb and 16-48% for bb and in Asian populations (1): 0-1% for BB, 10-22% for Bb and 77-90% for bb defined in groups of menopausal women). Our data did not differ from data published for European populations but they differed significantly from those published for Asian populations.

Our BMD data confirm the results from other population studies. In line with other investigators we observed higher BMD in FF carriers and lower BMD in ff carriers (4,5). The same trend was found with higher BMD in bb and lower values in BB carriers.

In our study group these with the ff genotype (6% of the controls and 28% of the cases) have 11.8% lower BMD at the forearm than the subjects with FF (54% of the controls and 25% of the cases). The heterozygotes Ff (40% of the controls and 48% of the cases) have an inter-
mediate BMD. The association between BMD and the genotype was also confirmed at the lumbar spine and femoral neck. Individuals with genotype ff have 11.7% lower BMD at lumbar spine and 7.7% lower BMD at femoral neck than FF. In our population the reduction in lumbar spine and femoral neck BMD was more substantial than that in forearm BMD (-36.5% and -33.3% vs. -22.7% at the forearm in ff and -24.8% and -26.6% vs. -15.6% at the forearm in FF).

Those participants carrying the BB genotype (11% of the controls and 35% of the cases) have 5.1% lower BMD at the forearm than subjects with bb (38% of the controls and 21% of the cases). The heterozygotes Bb (51% of the controls and 45% of the cases) have an intermediate BMD. The association of BMD with the genotype was confirmed also for the lumbar spine and femoral neck. Individuals with genotype BB have 13.2% lower BMD at lumbar spine and 12% lower BMD at femoral neck than bb. In our population the reduction in lumbar spine and femoral neck BMD was more substantial than that in forearm BMD (-36.2% and -37% vs. -23.6% at the forearm in BB and -23% and -25% vs. -18.5% at the forearm in bb).

In conclusion, this is a final report from a study examining the prevalence of two VDR genotype polymorphisms and their association with the forearm, lumbar spine and femoral neck BMD. We were able to show that the prevalence of the polymorphisms under study was similar to that in the typical European population and different from that in an Asian population. The impact of the different genotypes on BMD was substantial both at the lumbar spine and femoral neck. Our data underscore the potential benefit of screening subjects at risk for osteoporosis for their genetic predisposition.


The aim of the present investigation is to study the circadian rhythm of temperature, pulse, mood and vigor in patients treated with antidepressants from the new generation and to make a comparison with the classical antidepressants. For this purpose were examined 44 patients (25 were on moclobemide, 7 on venlafaxine, 7 on fluvoxamine and 4 were on citalopram). Temperature, pulse, mood and vigor were registered each hour from 7 AM to 10 PM with 2 or 3 night measurements. Data were analyzes by Halberg\'s cosinor method. Chronobiological characteristic of Moclobemid is near to Imipramin and co-medication of imipramin and amirptyline, and could disturb the pathologically stable rhythm. The established synchronization between rhythms of temperature, pulse, mood and vigor is a predisposition for good.

Циркадиален ритъм на температурата и пулса при лечение с Моклобемид, Венлафаксин, Флуоксамин и Циталопрам

Целта на настоящото изследване е да проучи циркадианния ритъм на температурата, пулса, настроението и подтиците при пациенти, лекувани с антидепресанти от ново поколение в сравнение с класическите антидепресанти. За тази цел ние изследвахме 44 пациенти (25 на моклобемид, 7 на венлафаксин, 7 на флувоксамин и 4 на циталопрам). Температурата, пулсът, настроението и подтиците бяха регистрирани всеки час от 7 до 22 ч. с две до три нощни измервания. Данните бяха анализирани чрез косинор-метода на Халберг. Хронобиологичните характеристики на Моклобемид са близки до тези на имипрамин и комедикация имипрамин и амитриптилин и могат да променят патологично стабилния ритъм.
therapeutic effect in AD, panic disorders and depressive states. In Fluoxetine temperature, pulse, mood and vigor are relatively synchronized, because of the absence of peak-hours of these parameters. Temperature and pulse peaks in Fevarin are desynchronized and their mesors are not significantly higher in comparison with the healthy persons. Mood and vigor are desynchronized too (mood is with a peak at 21,01 h, whereas vigor is without daily rhythm). The good therapeutic effect of Citalopram could be explained with the fact that could normalize the values of mood and vigors and the mesors of temperature and pulse, even when these four parameters are desynchronized. These data show that patients must use the drugs for a long period of time after clinical improvement in order to recover their disturbed circadian rhythm. Maybe future studies in greater number of patients will deliver more information about their use in psychiatric patients.

**Key words:**
circadian rhythm, temperature, pulse, moclobemide, venlafaxine, fluvoxamine, citalopram

**Introduction**

During the last 5-6 decades chronotherapy takes a serious place in the treatment of some psychiatric disturbances. It was established that typical for depression is the disturbed circadian rhythm of some biological human functions. It has been emphasized in recent studies (Stoyanov, 2008, Stoyanov, Machamer, Schaffner, 2010) that chronobiological factors and arguments are of critical importance in interpretation of correlations among neuroscience and psychiatry.

Seroquel XR – стъпка към хармония

XR за Х-перти

- Шизофренения, вкл. превенция на рецидив
- БАР мания
- БАР превенция на рецидив
- БАР депресия
- Голям Депресивен Епизод

AstraZeneca®
Сероquelle XR — Стъпка към хармония

• Ефективно с оцветяно основно
• Препоръчително за пациенти с ефирното
• Лечението с биполярно афективно разстройство.
• Заема значение в лечението на депресивни епизоди при пациенти с биполярно афективно разстройство.
• Предлаган е за пациенти при биполярно разстройство, при които се позволява кондиционална отмена на лечение със стрес.
• Допълнително лечение на аспирационна епидемия, при пациенти с депресивно афективно разстройство.
• Предлаган е за пациенти при биполярно разстройство, при които се позволява кондиционална отмена на лечение със стрес.
• Кинетика: Въведено е от 600 до 300 мг на ден.
• Дозата трябва да се увеличава една доза на ден.
• Препоръчително за пациенти с биполярно афективно разстройство.
• Издадено е от 600 до 300 мг на ден.
• Предлаган е за пациенти при биполярно разстройство, при които се позволява кондиционална отмена на лечение със стрес.
• Доза 300 мг на ден.
• Въведен е от 600 до 300 мг на ден.
• Препоръчително за пациенти при биполярно разстройство, при които се позволява кондиционална отмена на лечение със стрес.
• Доза 300 мг на ден.
• Въведен е от 600 до 300 мг на ден.
• Препоръчително за пациенти при биполярно разстройство, при които се позволява кондиционална отмена на лечение със стрес.
• Доза 300 мг на ден.
• Въведен е от 600 до 300 мг на ден.
• Препоръчително за пациенти при биполярно разстройство, при които се позволява кондиционална отмена на лечение със стрес.
• Доза 300 мг на ден.
• Въведен е от 600 до 300 мг на ден.
• Препоръчително за пациенти при биполярно разстройство, при които се позволява кондиционална отмена на лечение със стрес.
• Доза 300 мг на ден.
• Въведен е от 600 до 300 мг на ден.
• Препоръчително за пациенти при биполярно разстройство, при които се позволява кондиционална отмена на лечение със стрес.
• Доза 300 мг на ден.
• Въведен е от 600 до 300 мг на ден.
• Препоръчително за пациенти при биполярно разстройство, при които се позволява кондиционална отмена на лечение със стрес.
• Доза 300 мг на ден.
from circadian to ultradian rhythm (A. Bicakova-Rocher et al., 1989; 1996).

W. Duncan & T. Wehr (1988) supported the idea, that the „circadian pacemaker” in endogenous depression is destroyed, and the use of some antidepressants could improve the disturbed circadian rhythm. In clinical practice sleep disturbances and depressive symptoms in depressive patients could be improved with effective antidepressant medication. Some of them could delay, others could advance the phase. So the most important idea of therapeutics is to synchronize the disturbed circadian rhythm in patients with Affective disorders/AD/, Schizophrenia. For this purpose are used specific chronobiological methods as sleep deprivation, bright therapy in patients with depression and bulimia nervosa, dark therapy for patients with acute mania (20), electric-acupuncture for depressive patients with pathologically stable rhythm (N. Madjirova et al. 1997).

The chronobiological characteristics of some antidepressants are investigated on animals. They put some theoretical aspects of their mechanisms, but the questions connected with practice are quite different and still undecided. The data about the new generation of antidepressants are not well studied. We had examined the circadian rhythm of temperature and pulse and the stability of rhythm of mood and vigor in various psychotropic drugs (antidepressants, neuropeptic and tranquilizers). Most of the publications of the new generation of antidepressants (citalopram, fluvoxamine) are connected with their clinical characteristic, but almost nothing is written about their chronobiological features.

The aim: in this study we would like to pay a special attention to antidepressants from the new generation as Moclobemid (Aurorix), Efexor (Effectin = Fluoxetine), Citalopram (Citalopram = Cipralex). Our aim is to establish the circadian rhythm of temperature and pulse and to some of them the stability of rhythm of mood and vigor in depressive patients and to make a comparison with the classical antidepressants such as Imipramine, Amitriptyline, Clomipramine and Maprotiline.

In the present investigation were included 44 patients (27 were with AD and 15 with ND (anxiety and panic disorder). The patients were on moclobemid (26 patients, followed in 109 days, 11 were with AD, 15 were with ND), venlafaxine – 7 patients studied 63 days, fevarin – 7 patients studied 45 days and on citalopram – 4 patients followed in 38 days. The control group consists of 65 healthy individuals.

• Examination of the circadian rhythm of temperature, pulse, mood and vigor: temperature and pulse were measured each hour from 7 AM to 10 PM with 2 or 3 night measurements with mercury thermometer and the pulse rate was registered for 1 min.

• Data were analyzed by the method of Halberg’s Cosinor Analysis.

• Hamilton’s depressive scale was used to determinate the mental state of the patients.

• We made a comparison with a control group of healthy persons and patients with AD and ND before and after medication with some of the classical antidepressants, from our previous examinations.

• Study the stability of the rhythm of mood and vigor in patients on Moclobemid, Venlafaxine and Citalopram.

• The stability was measured by our own scale that was standardized on 481 psychiatric patients and 141 healthy persons. The examined persons registered the rhythm of mood and vigor every day for a period longer than a month (N. Madjirova; 1992; 1995; 2006). For part of the patients we have their rhythm of temperature and pulse. They were registered each hour from 7AM to 10 PM with 2-3 night measurements at least for a week.

• One-day examination of the circadian rhythm could not have measured the full cycle of the circadian rhythm predominating in the individual patients.

• When the follow-up was at least for two or three weeks, it was possible to identify the predominating rhythm (arrhythmic, morning, evening, fluctuating) in the individual patients and to characterize its stability. We studied each patient for stability of diurnal fluctuations of
emotions and vigor, and for some of them of temperature and pulse. Data were analyzed by Cosinor Method of Halberg.

• During the long-term investigation 3 types of stability of the circadian rhythm emerged (see graphic 1):
  • Stable type rhythm – the substitution of one type of circadian rhythm for another over greater intervals of time, for 1 or 2 weeks (type I-a), and no change of the rhythm was observed during the study (type II).
  • Unstable rhythm – when changes occurred almost daily (type I-b), or periods of a single type rhythm alternated with frequent changes of the rhythm – type III (N. Madjirova, 1992; 1995; 2006).

### Results and discussion

Data of temperature and pulse mesors and their peak-hours of the various drugs are given at table 1. Moclobemid (Aurorix) – is a new generation (RIMA - Reversible Inhibitors of MAO-A). It is with a very good effect for old patients, for anxiety disorders (R.G. Priest, 1992), social phobia (M. Versiani u E. Nardi, 1994) and it is with a good effect on the REM-phase of the sleep. Moclobemide was used in 26 patients (11 with AD – depressive episode and 15 with ND, social phobia with panic attacks). The daily dose was between 150 and 300 mg. in co-medication with carbamazepine (CBZ) about 200-600 mg. daily.

The circadian rhythm of temperature and pulse was followed in between 2 and 5 days. On table 1 is given its chronobiological characteristic: for the whole group temperature and pulse mesors and their peak-hours are not different from the group of healthy persons. In our previous study (N. Madjirova, 1997) was established that chronograms of the antidepressants are different when they are used by patients with AD and ND. So we make a comparison of the chronograms of moclobemid in patients with AD and ND.

We established that temperature and pulse mesors are higher, but not significantly, in the group of ND. The peak-hours in AD delay in...
comparison with ND with 2.36 h for temperature and 2.09 for pulse. Typical for patients (AD and ND) on moclobemid is the synchronization between temperature and pulse chronograms (see table 1). The good improvement of ND with social phobia and panic attacks could be explained with synchronization between their peaks that are not different from the healthy persons (16.02 h; 16.18 h for temperature and 14.58 h; 14.15 for pulse). This synchronization could also explain the good effect in old patients, who are characterized with phase delay in the old persons. Such kind of synchronization could not be found in patients who were treated with other drugs, with the exception of the mood stabilizer normothymine and co-medication of three-cycle antidepressants and carbamazepine. We have studied 1 patient, followed in for 1 week on normothymine and the peaks of temperature (17,23) and pulse

(18,21) were synchronized. The good therapeutic effect of depressive patients on normothymine is connected with its ability to normalize their phase.

**I. Some chronobiological features of the circadian rhythm of Moclobemid:**

1. **Moclobemid (total in AD and ND):**
   • Temperature and pulse mesor are synchronized;
   • The peak-hours of temperature and mesors are not different by the values of the healthy persons.

2. **Chronobiological features of Moclobemid in AD:**
   1. Rhythm of mood and vigor are desynchronized – the peak-hour of mood is at 19,09, whereas the vigor is without daily rhythm.
   2. Temperature and pulse peak-hours are

<p>| Table 1. | Temperature and pulse mesors and their peak-hours of moclobemid, efexor, fevarin and citalopram determined by F. Halberg cosinor analyzes. |
|-----------------------------------------------|</p>
<table>
<thead>
<tr>
<th><strong>Dg</strong></th>
<th><strong>Drug</strong></th>
<th><strong>n of patients</strong></th>
<th><strong>n of days</strong></th>
<th><strong>Temperature mesor</strong></th>
<th><strong>Peak Hour</strong></th>
<th><strong>Significance</strong></th>
<th><strong>N of days</strong></th>
<th><strong>Pulse mesor</strong></th>
<th><strong>Peak Hour</strong></th>
<th><strong>Significance</strong></th>
<th><strong>Synchronization</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AD</strong></td>
<td>Moclobemid</td>
<td>11</td>
<td>27</td>
<td>36,339</td>
<td><strong>18,37</strong></td>
<td><strong>Yes</strong></td>
<td>15</td>
<td>69,09</td>
<td><strong>18,08</strong></td>
<td><strong>Yes</strong></td>
<td><strong>Yes</strong></td>
</tr>
<tr>
<td></td>
<td>Efexor</td>
<td>7</td>
<td>63</td>
<td>36,423</td>
<td>16,14</td>
<td>No</td>
<td>59</td>
<td>77,71</td>
<td>13,52</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Fevarin</td>
<td>7</td>
<td>45</td>
<td>36,447</td>
<td><strong>19,1</strong></td>
<td><strong>Yes</strong></td>
<td>40</td>
<td>79,06</td>
<td>3,03</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Citalopram</td>
<td>4</td>
<td>38</td>
<td>36,148</td>
<td><strong>15,41</strong></td>
<td><strong>Yes</strong></td>
<td>38</td>
<td>71,04</td>
<td>11,31</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>AD- before therapy</td>
<td>100</td>
<td>100</td>
<td>36,416</td>
<td>16,01</td>
<td><strong>Yes</strong></td>
<td>100</td>
<td>82,91</td>
<td>11,44</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td><strong>ND</strong></td>
<td>Moclobemid</td>
<td>15</td>
<td>82</td>
<td>36,592</td>
<td><strong>16,02</strong></td>
<td><strong>Yes</strong></td>
<td>58</td>
<td>83,30</td>
<td>14,58</td>
<td><strong>Yes</strong></td>
<td><strong>Yes</strong></td>
</tr>
<tr>
<td></td>
<td>ND - before therapy</td>
<td>81</td>
<td>81</td>
<td>36,48</td>
<td>16,19</td>
<td><strong>Yes</strong></td>
<td>46</td>
<td>80,47</td>
<td>14,17</td>
<td><strong>Yes</strong></td>
<td><strong>Yes</strong></td>
</tr>
<tr>
<td><strong>Healthy persons</strong></td>
<td>65</td>
<td>65</td>
<td>36,387</td>
<td><strong>16,18</strong></td>
<td><strong>Yes</strong></td>
<td>55</td>
<td>74,83</td>
<td>14,15</td>
<td><strong>Yes</strong></td>
<td><strong>Yes</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>Moclobemid</td>
<td>26</td>
<td>109</td>
<td>36,47</td>
<td><strong>17,17</strong></td>
<td><strong>Yes</strong></td>
<td>73</td>
<td>76,19</td>
<td>16,35</td>
<td><strong>Yes</strong></td>
<td><strong>Yes</strong></td>
</tr>
</tbody>
</table>

* AD – affective disorders, ND – neurotic disorders
synchronized.

3. Individual chronograms of mood and vigor show that only 48.15% are synchronized, 22.22% are desynchronized and 29.62% show no daily rhythm. Temperature, pulse, mood and vigor are desynchronized in 84.62% of the group.

3. Some chronobiological features of Moclobemid in ND during therapy
   • Mood and vigor exhibit no daily rhythm. They are relatively synchronized, because of the absence of daily fluctuation.
   • Temperature and pulse peak-hours are synchronized and the values of their mesors and peaks are similar with the healthy persons.
   • Temperature and pulse peak-hour are desynchronized with mood and vigor peak-hours.
   • Individual chronograms show, that the 4-th parameters are desynchronized in 92.31%. Only 22.22% of pulse and temperature are synchronized, whereas mood and vigor are synchronized in 64.29%. Daily rhythm of temperature and pulse disappeared in 44.44%. Temperature and pulse are synchronized in 66.67% of the cases.

As we see the individual chronobiological characteristic of patients on moclobemid are not so perfect in comparison with the chronobiological characteristic of the total group. But we must not neglect the fact that moclobemid is one of the antidepressants with very good chronobiological data of temperature and pulse, that are perfectly synchronized and the values of their peak-hours and mesors are the same as of the control group, especially for patients with ND. All this facts explain the good improvement of patients with ND (panic disorders).

Stability of the rhythm of moclobemid:

Stability of the circadian rhythm was followed in 19 of the patients (8 were with AD, 11 with ND, from which 9 were with panic disorders). To all of them was followed in the rhythm of mood, vigor, temperature and for the ND and pulse. For 6 of the patients with AD we have their circadian rhythm before medication, and for 3 of them we have an impression for their stability. Data of the parameters are given at table 2.

Stability of the rhythm in patients with AD

• Before medication there is registered no daily rhythm of mood, vigor, temperature and pulse.
• After medication – in this group were included 8 patients with AD, who were on Moclobemid and CBZ, and were followed in at least 3 weeks. The values of mood and vigor are increased significantly and correlate with their clinical improvement. Their peak-hours are at 21,54 and 21,36 and are synchronized. This data support the idea of the old psychiatrists and our previous results that evening type rhythm dominates in depressions. Temperature mesor decreased after their improvement and the peak-hour is not different from the peak of healthy persons. For the rhythm of mood and vigor dominate unstable type rhythm (85.71%), whereas for temperature is 60.00%. This type of rhythm stability is near to the stability of Imipramine.

Stability of rhythm in patients with ND – the results in the group with panic disorders are very good – values of mood and vigor speak for a very good clinical improvement. The most important is that the 4 parameters (mood, vigor, temperature and pulse) are synchronized and their peak-hours are in the afternoon and not different from the peaks of the healthy group. This data indicates that co-medication of moclobemid and CBZ is very good for patients with panic disorders. The other 2 neurotic patients with depressive syndrome and vegetative symptoms show no daily rhythm of vigor, temperature and pulse. Even the examination is only on 2 cases, their values are not so perfect, as the results of the patients with panic disorders. The daily rhythm of temperature and pulse disappears, but mood and vigor are synchronized in co-medication of Moclobemid, CBZ and Antelespin in patients with AD.

Common for the group of Moclobemid is:

1. Mood and vigor, and temperature and pulse are well synchronized, that could explain the clinical improvement of the patients.
2. The stability of the rhythm: dominates
Table 2. Some chronobiological features of patients treated with Moclobemid.

<table>
<thead>
<tr>
<th>Data parameters</th>
<th>AD-recurrent depression Before therapy</th>
<th>AD-recurrent depr. Co-medication with CBZ</th>
<th>ND-panic disorder Co-medication with CBZ</th>
<th>ND-depr. Syndrome and cephalgia</th>
<th>Co-medication with CDZ &amp; Antelespin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MOOD</strong></td>
<td>n-patients: 6, n-day: 17, Mesor: 140.97 +/- 120, Peak-hour: 18,07, Significance: 4/1</td>
<td>6, 8, 9, 2</td>
<td>71, 303,93 +/- 33, 15,59(14,18-18,49)</td>
<td>2, 13, 332,8 +/- 57,9</td>
<td>2, 23, 378,14 +/- 36, 19,56(18,48-20,59)</td>
</tr>
<tr>
<td></td>
<td>Stable rhythm: 1, 75%</td>
<td>4/3, 1 (14.29%), 785,29%</td>
<td>48/23, 2 (40,0%), 5 (60,0%)</td>
<td>11/2, 0</td>
<td>2, 100%</td>
</tr>
<tr>
<td></td>
<td>Unstable: 2, 50%</td>
<td>1, 785,29%</td>
<td>5 (60,0%)</td>
<td>2 (100%)</td>
<td>1, 50%</td>
</tr>
<tr>
<td><strong>VIGOR</strong></td>
<td>n-patients: 6, n-day: 17, Mesor: 124,32 +/- 111, Peak-hour: 15,20, Significance: 3/2</td>
<td>6, 8, 9, 2</td>
<td>71, 290,20 +/- 34, 15,39(13,31-17,58)</td>
<td>2, 13, 246,09 +/- 65, 12,04</td>
<td>2, 23, 376,52 +/- 38, 19,51(18,48-20,59)</td>
</tr>
<tr>
<td></td>
<td>Stable rhythm: 2, 50%</td>
<td>4/3, 1 (14.29%), 785,29%</td>
<td>35/36, 2 (40,0%), 5 (60,0%)</td>
<td>7/5, 0</td>
<td>2, 100%</td>
</tr>
<tr>
<td></td>
<td>Unstable: 1, 25%</td>
<td>1, 785,29%</td>
<td>5 (60,0%)</td>
<td>2 (100%)</td>
<td>1, 50%</td>
</tr>
<tr>
<td><strong>TEMPERATURE</strong></td>
<td>n-patients: 6, n-day: 19, Mesor: 36,72 +/- 0.19, Peak-hour: 17,12, Significance: 5/1</td>
<td>6, 8, 9, 2</td>
<td>68, 36,58 +/- 0.12, 16,16(15,12-18,08)</td>
<td>2, 9, 36,619 +/- 0.1, 13,31</td>
<td>2, 23, 36,519 +/- 0.2, 15,28</td>
</tr>
<tr>
<td></td>
<td>Stable rhythm: 1, 25%</td>
<td>4/3, 3 (40,0%), 5 (60,0%)</td>
<td>42/26, 3 (50,0%), 3 (50,0%)</td>
<td>8/1, 0</td>
<td>2, 100%</td>
</tr>
<tr>
<td></td>
<td>Unstable: 1, 25%</td>
<td>1, 3 (50,0%)</td>
<td>3 (50,0%)</td>
<td>2 (100%)</td>
<td>1, 50%</td>
</tr>
<tr>
<td><strong>PULSE</strong></td>
<td>n-patients: 6, n-day: 46, Mesor: 84,42 +/- 1,4, Peak-hour: 15,47(14,18-17,16, Significance: 29/17,</td>
<td>6, 9, 2</td>
<td>70,72 +/- 19,2, 12,40</td>
<td>2, 9</td>
<td>1, 6</td>
</tr>
<tr>
<td></td>
<td>Stable rhythm: 1, 33,33%</td>
<td>1, 3 (33,33%)</td>
<td>2 (100%)</td>
<td>1, 50%</td>
<td>1, 50%</td>
</tr>
<tr>
<td></td>
<td>Unstable: 3, 66.67%</td>
<td>3 (66,67%)</td>
<td>2 (100%)</td>
<td>2/4</td>
<td>1, 50%</td>
</tr>
</tbody>
</table>

Temper. - temperature
R/Arhyth. - relations between patients with rhythmic values of the parameters/arrhythmic values.

the unstable rhythm and this data are near to mipramin, co-medication of imipramine and amitrtryptiline stability and this effect could destroyed the pathologically stable rhythm, that

Idomminates in depressive patients with AD and some ND.
Conclusion:

Chronobiological characteristic of Moclombox is close to Imipramine and co-medication of imipramine and amitriptyline, and may disturb the pathologically stable rhythm. The established synchronization between rhythms of temperature, pulse, mood and vigor is a predisposition for good therapeutic effect in AD, panic disorders and other depressive states.

Fluoxetine

(Efexor = Effectin = Fluoxetine): this antidepressant is from the new generations of SSR. In this group are included 7 patients with AD, aged between 25 and 54 years (middle age 41.6 years). 5 of them are with recurrent depression and 2 are with bipolar disorders (the present episode is depressive). 2 of the patients were followed for 2 days, 2 – for 4 days, 1 – 9 days, 1 – 17 and 1 – 25 days. So for 3 of them we have an impression for their stability.

Chronobiological characteristic:

1. Individual chronograms:
   2. In 3 of the patients the daily rhythm of the four parameters (temperature, pulse, mood and vigor) disappeared and so they are relatively synchronized because of the absence of daily rhythm. The other 2 patients are desynchronized – there is no daily rhythm of mood and vigor, one patient is with peak-hour of temperature, and 1 is with a peak-hour of the pulse. So the 4 parameters in the 4 patients are desynchronized.

3. Group characteristics:
   The mesors of the four parameters are almost the same as the mesors of the control group of the healthy persons. Temperature, pulse, mood and vigor are relatively synchronized, because of the absence of peak-hours of these parameters. If we make a comparison with the classical antidepressants we established that his chronobiological characteristic is almost the same as of imipramine, trimipramine, nomiphenamine, hydiphen, co-medication of imipramine and amitriptyline. Their parameters are relatively synchronized. Their pulse rate is not quickened and the values are the same as of healthy persons and patients on hydiphen. (N. Madjirova, 1995; 1997; 2006).

Conclusion:

There should be stressed the fact, that temperature, pulse, mood and vigor in are synchronized, because of the absence of daily rhythm of these parameters. So they are relatively synchronized.

Fluvoxamine = Fluvoxamine

Fevarin is an inhibitor of serotonin re-uptake. It is with a very good effect in obsessive-compulsive disorders. We studied 7 patients (5 with AD, recurrent depression, 2 with ND, panic disorders), aged between 29 and 49 years (the middle age is 39.4 years. Their dose was between 75 and 150 mg. daily.

L. Demisch et al. (1996) studied the chronobiological effect of fluvoxamine on rat pineal serotonin and melatonin metabolism. They established that its chronobiological effect is the most strong in rats when it is given at 4,00 h PM. This effect could be explained with the higher sensitivity of 5-HT in the CNS. They are connected with the phase changes of 5-HT, that appeared 7 hours after the disappearance of light.

W. Duncan, K. Johnson u T. Wehr (1995) established that antidepressants could delay the circadian rhythm of body temperature, without changing its amplitude and mesor in experimental animals (rats). But there were no data about these changes when the drugs are given for a longer period of time. They have established that hypothalamic temperature delayed the phase of temperature in rats treated with some antidepressants (Clorgiline, Fluoxetine, Lithium carbonate). These results correlate with our data – temperature peak-hour (17,10) 1,52 hours) is later 2,52 h in comparison with the healthy persons (see table 1).
**Chronobiological characteristic:**

- Individual chronograms: rhythms of mood and vigor in 6 of the patients, with the exception of 1 with panic disorder, are synchronized, whereas the rhythm of temperature and pulse are desynchronized. The relation between rhythmic and arrhythmic cases for mood and vigor are 71.43%/28.57%, whereas for temperature and pulse are the opposite (28.57%/71.43%).

- **Group characteristics:**
  1. Temperature and pulse mesors are higher, but not significantly higher in comparison with the healthy persons. Pulse rate shows no daily rhythm, and is desynchronized with temperature rhythm (see table 1). Mood and vigour are desynchronized too (mood is with a peak-hour at 21.01 h, whereas vigour is without daily rhythm).
  2. Stability of rhythm: stability has been registered in 4 of the patients.
  
**Conclusion:**

The good therapeutic effect of Citalopram could be explained with the fact that it normalizes the values of mood and vigor and the mesors of temperature and pulse, even these four parameters are desynchronized.

All these results lead us to the idea, that even clinical improvement rhythm processes are not well stabilized. So we must have in mind the experimental results on rat of M. Poppei et al. (1982) and R. Rose et al. (1982), that the treatment of animals with experimental neuroses for 1 month is not sufficient, as their desynchronization continues even their clinical improvement. According to them chronic desynchronization of the biological rhythm are one of the reasons for ND.

Some of the established chronobiological data put some important questions about the treatment of the psychiatric patients.

• How many days/months the antidepressant therapy must continue?
• Is not possible co-medication to course desynchronization?
• What is the effect of the various antidepressants on the different nosological groups (AD, ND) and their subgroups?
• What is the influence of the seasons of the year, hours of the day, sex and age?
• What is the role of pharmacokinetics?

**Acknowledgments:** The authors are grateful to Nedialka Petrova, head assistant in the Department of Social Medicine in MU-Plovdiv and Nedelcho Delchev, who worked in Bulgarian Academy of Sciences, Plovdiv, for their competent help in interpreting the data and statistical analysis.


A study has been conducted on 928 people from three professions (doctors, teachers and administration staff) and the influence of modern stresogenic factors and their psycho emotional influences on the individual.

We analyzed the effect of 106 stresogenic factors divided into 4 categories – socio-economic, professional, family environment and work environment – in three factor areas – psychological, physiological and factors of the work environment.

The effect of these stresogenic factors has been calculated using the method of J. Hristov, with the cumulative effect of the factors being studied in addition to their individual effect.

There is demand for working strategies, aimed both at the general population and individuals, which take into account the factors and risks associated with every living environment.

Извършени са наблюдения на 928 души от три професии (лекари, учители и административни служители), като е анализирано влиянието на съвременните стресогени фактори и техните психоемоционални въздействия върху индивида. Подчертана е необходимостта от разработване на действени стратегии за ограничаване и намаляване на стреса, имащи общо-популационна и индивидуална насоченост, които са отчитат особеностите на всяка жизнена среда и нейните въздействия.

Разработен е модел за превенция и управление на стреса, в който са разгледани целите, начините, подходите и мерките за ограничаване и намаляване на стреса и са конкретизирани задачите на държавните, обществени и браншови организации в тази насока.
A model for the prevention and control of stress has been developed, which reviews the aims, methods and applicable preventive measures as well as the associated tasks that national, public and private organisations need to complete to this end.

The different ways of limiting and reducing stress have been reviewed (active-passive).

There are three main strategies in worldwide practice. Every strategy has three goals: prevention, timely reaction and rehabilitation. These must be clearly aimed towards the organisations or individuals and correspond to the subject-object interaction.

In order to improve the work done to combat stress there are three types of measures used: primary, secondary and tertiary.

**Key words:**
stress, factors, psychosocial influences, strategies for prevention and control
The changes associated with stress and its effects on both temperament and structural-psychological qualities of personality are the subject of intense scientific research. Most frequently they are associated with moral disintegration of society, the changed attitudes toward employment, others, towards oneself, one’s interests and tendencies, spiritual and aesthetic values (7,8).

The opinion that the strategies for prevention and control of stress require a social policy that takes into account the varying influences of different living environments and the risk factors they pose to the health of the individual is reinforced. These strategies need to create appropriate conditions for the inclusion of organisations and individuals, so that they can effect a direct influence on both the environment and the way of life of those involved in order to stimulate adaptation to the new social requirements (3, 4, 5).

Existing social practice puts more focus on the study of stress and determining its negative effects, with not enough attention being paid to the evaluation of risk factors and the possibilities for making connections between harm done and the resulting negative health effects (1, 2).

This necessitates the establishment of both rules and an institutional frame which specify the scientific studies and prophylactic courses for combating stress (6, 7, 8).

An evaluation of the acting legislations for prevention and control of stress, with measures of an individual and general character being suggested to improve their effectiveness.

Results and discussion

The different ways of limiting and reducing stress have been reviewed (active-passive). It has been proven that the active overcoming of stress is aimed at changing stress-generating situations with the intent of removing stresogenic factors, while the passive approach involves adapting to the situation and accepting it as unavoidable, which often leads to distress. When evaluating which course of action to take the personal qualities of the individual as well as the present material and social resources must always be taken into account.

We analyzed the effect of 106 stresogenic factors divided into 4 categories: – socio-economic, professional, family environment and work environment - in three factor areas: – psychological, physiological and factors of the work environment.

The effect of these stresogenic factors has been calculated using the method of J. Hristov, with the cumulative effect of the factors being studied in addition to their individual effect.

The complexity of stresogenic psychosocial influences requires good planning, coordination and control of preventive measures, as well their stage-by-stage implementation: determining negative factors, evaluating the corresponding risks, applying appropriate control strategies, monitoring their effectiveness, re-evaluating the risk, analysis of the necessary information, training those at risk and etc.

In practice there are two strategic approaches: standard (problem oriented) to evaluate physical risks and (emotionally oriented) for the evaluation of psychosocial risks. The evaluation of physical risks is clearer and begins with analyzing the risks and harms leading to useful information to evaluate the result. With psychosocial risks there is no unified classification of the degrees of harm and influence monitoring is complicated, as the harm is harder to perceive than physical inequality and accidents.

In worldwide practice there are three main strategies: situational (coping strategy), disposi-
### Goals and tasks of the model

**Performance evaluation** → **Aim groups**

**Monitoring** → **Institutional frame**

**Activities** → **Implementers of the model**

**Results and review**

**Stages of realisation**

---

**Figure 1.** Structure of the model for limiting stress in doctors, teachers and administrative staff

---

**Information gathering on primary stressogenic factors**

**Monitoring** → **Evaluation of stress condition**

**Execution of planned actions** → **Performance evaluation**

**Determining and planning action**

**Distribution of planned actions**

---

**Figure 2.** Algorithm for applying the model for limiting stress in doctors, teachers and administrative staff
national (coping style), and emotionally focused coping (6, 8) which reflect the various cognitive and behavioural mechanisms for overcoming and reducing stress.

Every strategy has three goals: prevention, timely reaction and rehabilitation. These must be clearly aimed towards the organisations or individuals and correspond to the subject-object interaction.

In order to improve the work done to combat stress there are three types of measures used: primary, secondary and tertiary. It has been proven that the primary type is the least popular, because changing the nature of the labour or its overall organisation is a complicated process. Secondary measures are concerned with activating personal control of stress through different techniques (behavioural skills, special programmes, relaxation and others). Tertiary measures address individuals experiencing breakdowns or with harmful habits.

Over the course of the last decade several coping strategies have been presented, but only a small number of them have value or give an accurate assessment. Institutions which coordinate the politics, actions and programmes for overcoming stress. The necessity of public awareness of these problems and taking active decisions becomes evident.

Based on the conducted study, a model for the prevention and control of stress has been developed (fig.1)

**Conclusion**

Based on the conducted studies national, public and private organisations tasks have been determined for the reason of stress control and improvement of the overall health.

**References**

2. Cox T. 1987, Stress, coping and problem solving. Work &Stress 1, 5-14
5. Hristov. Zh and D. Stoyanov, Management psychology in health care, Foreword by G. Stanghellini, Kamea design, 2009

**Address for correspondence:**

**Todor Stoev assoc. prof.**
Department of Health Management,
Medical University, Plovdiv
Vassil Aprilov str. 15-A
Plovdiv 4002

**Доц. Тодор Стоев**
ФОЗ, Медицински университет, Пловдив, ул Васил Априлов 15-А, Пловдив 4002
Mastering the science of medicine means following two inter-related paths. The first, is the quest "to learn and know". It involves a comprehensive study of the human body and the dynamic relationship of "life - health - illness - death". The second, is the aim "to find the right cure". It utilizes all acquired knowledge to intervene in the above-mentioned relationship in favor of prolonged life and health. Curing and healing a patient, however are two different concepts. Healing utilizes the science of medicine to cure the body, but also goes a few steps further to incorporate empathy (relating to the patient's specific physical and emotional state) and ethics (applying the science of medicine in a respectful and humane way) into the equation. It is well-known that the constant rise in human population places a strain on limited resources, the availability of medical specialists inclusive. Coupled with a prolonged period and the high
cost of educating such, as well as the competitive drive of universities to get funding, it changes the entire focus of the profession. Sadly, the impetus nowadays is either to engage in ground-breaking technologically-driven research on genetics, push-sell drugs and prosthetics, or, at the very basic level, cure the largest number of hospitalized patients to a somewhat relative state of health and do so fast. Such prioritization creates flaws in the medical education system that divert medicine away from the art of healing towards simply the business of curing. The results for the medical students are: excessive stress, inadequate factual preparation and emotional immaturity. The results for the patients are: more and, increasingly, pharmacologically suppressed pain, longer recovery to health and a sense of diminished self-importance.

*Key words:* medicine, empathy, ethics

*What is medicine?*

Medicine is old. As old as the life itself. Wherever there is a living organism, there is a dynamic state of relative well-being, normal function disturbance, healing and death. Death is not immediate and permanent. Nor is it always the final stage of existence. The key to stave it off is energy sustenance. As long as energy exists or could be swiftly reintroduced, processes such as cell acclimatization and mutation can bring back life numerous times, possibly, indefinitely.

Before humans, medicine's only practitioner was nature. It would counteract the effects of climate and chance. The aim was the continuation of life - in any shape and form, conducive to its survival. There was no imperative to sustain the greatest number and variety of organisms alive. Species would develop, mutate into new ones or perish. Life itself would not.

*The human exception*

Humans developed as a species and nature's dominance as the sole „life decision-maker“ was disputed. Humans, however, developed as frail organisms. Small in stature, soft both on the inside and the outside. No external
skeleton, venom, color-changing, claws or fangs for protection. Relatively narrow band of suitable life conditions. One notable exception - big and more evolved brains.

To ensure survival and the continued domination of their species, humans had to find a way to counteract nature's indiscriminate practice of medicine and start healing themselves. Hail the birth of anatomy observation and human medicine.

All good, but where is the catch? Intraspecies' instinctive drive to singularly ensure their specific genetic patterns' survival and predomination.

To correct this undesired variable, humans gradually introduced artificial constructs such as „marriage”, „religion”, „law”, „rights”, „justice”, „dignity”. All of them contribute to the prescription and acceptance of medical practices and traditions, centering on the importance of every single human being.

One issue still persists. In order to enforce compliance over an ever-growing population and ration limited life-sustaining resources, humans had to introduce two other artificial concepts - „money” and „private property”. If that was not enough, smaller units of humans proved to be easier manageable than larger ones; hence, the decompartmentalization of the human species into separate governing entities (now called „states”) came into being.

Such a development, was not altogether good news for medicine in two ways. First, although medicine centers on the human as an unit, and, through it, the human species as a whole, it employs the use of natural and synthetic substances, as well as other highly specialized products, such as surgical instruments or life support machinery. Their conception and production in a reality where „money” and „private property” exist, needs adequate Phoenician coverage. The training of medical specialists is another costly affair.

So, who pays for the expense? Humanity through its artificial construct - the state, or individual humans in need of medical service? Does money and the need for it deflect from human medicine’s purpose - to prolong and diversify human life?
The observance of medical traditions is another obvious loser. The major division, of course, would be in the domain of “religion”, especially through its major varieties – Christianity, Islam and Hinduism, each of which has a slightly different take on life, medicine inclusive. However, not all news is bad news. Ever developing Schools of Medical Thought, transgressing religious contention appeared and are now accepted by more than one state. By far, the predominant, albeit not the most tolerant and inclusive (this place is reserved for Buddhism), is the evolutionized version of the Ancient Greek School of Thought. What is considered as “modern” human medicine, builds on it.

According to its precepts, mastering the art of medicine means following three inter-related paths. The first, is the quest “to learn and know”. It requires a comprehensive study of the human body and a scientifically-based understanding of the relationship “life - health - illness - death”. The second, is the aim “to find the right cure”. It utilizes medical knowledge to intervene in favor of prolonged life and “better quality” of it. The third one, relates to personal integrity and moral conduct. Its guiding principles are – “always give your best”, “do no harm” and “be ethical”.

The first two paths are the major accent. They are structural, logic-based and explicit in their purpose. As such, they concentrate on students’ efforts to develop themselves as successful medical specialists. The safeguard of the human species is a byproduct.

The last path is complementary. It is based on the “good will” of each physician and is, therefore, more discretionary in nature. Full of artificial constructs, it is intended to combat human instincts in the name of “the greater good of the greatest number”. It does so by appealing to emotional intelligence.

**Issues**

With that in mind, one major downside of this School of Medical Thought is the selection process of the would-be physicians. The vast amount of data that needs to be assimilated in medical school has favored an entry exam system testing factual knowledge in exact sciences only.

Medicine however, is about inter-related data. The ability of students to structure this data into useful, easy-to-extrapolate from knowledge systems remains unchecked.

There is no reference as to ethics, philosophy, empathy or effective communication skills either. Without an adequate network of checks and balances over human instincts, the power of knowledge over life and its continuation that physicians are entrusted with could be easily abused.

The problem is exacerbated by the fact that medicine offers high social reputation and, not rarely, significant material returns. Who guarantees that the most suitable candidates are the ones that are being selected?

There is some consolation, of course, in the fact that, upon graduation, all medical practitioners must take what is considered to be the “highest” and “longest observed” oath of acceptable and predictable conduct. Who vouches on its proper observance and by what standards? The peers? Humanity? God?

Also, without evidence of emotional intelligence, is this oath enough to ensure quality of service?

**The future**

Current debate on these issues remains inadequate. Within the medical community, there are some polemics about “missing elements” in the practice of medicine or the dehumanization of the profession, but they all fall under the category of “empty talk and no action.”
Policy makers are busy with hospital management and medical insurance. No one else pays any attention. There is simply not enough steam to trigger necessary change. But, there is hope.

One way to work with the present system and still move forward is to examine what lies in between the medical school selection process and the taking of the Hippocratic oath - namely, medical education itself. Can we, the established medical professionals and pedagogues, do something to influence outcomes?

After a thorough check on life philosophy, ethics, the structural and emotional status of each medical student at the beginning of their studies, there is a battery of measures that could boost results:

• more comprehensive study of human bio-ethics
• consistent measurement and follow-up on emotional development
• involvement in non-profit social work as part of compulsory medical education
• non-monetary incentives to participate in scientific research, while still studying
• rotational practice in all major clinics

In other words, the focus of medical education itself must shift from the present, impersonal view of future physicians as well informed, life-and-death decision-makers to a broader, more comprehensive perspective.

From the onset of their studies, each student of medicine must be perceived as a separate, unique universe. Besides, knowledge acquisition, his/her internalization processes (emotional ones inclusive) must also be cared for, on an individual basis.

References


7. Racine, Eric. „What role should emotions and empathy play in ethical decision making?“ Canadian Psychiatry Aujourd’hui. 2.6 (December 2006).


Address for correspondence:

Valeria Tananska
Department of Anatomy, Histology and Embryology, Medical University Plovdiv
Vassil Aprilov str. 15-A, Plovdiv 4002

Валерия Тананска
Катедра анатомия, хистология и эмбриология, Медицински университет – Пловдив, ул. „Васил Априлов“ 15А, Пловдив 4002
Women with Cardiac Syndrome X- Depressive Symptoms and a Possibility for Their Assessment

Svetlin Tsonev¹, Temenuga Donova¹, Maria Milanova²
¹Medical University, Sofia
²University Hospital „N. I. Pirogov”
*Corresponding author

Abstract

The cardiac syndrome X includes patients, mainly women, with the triad of angina pectoris, a positive exercise electrocardiogram for myocardial ischaemia and angiographically smooth coronary arteries. The most manifest clinical symptom in those patients is the chest pain. In most cases the syndrome is associated with debilitating symptomology, increased psychological morbidity and a poor quality of life.

Aim of the current study is to make a cross sectional study of the depressive syndrome among women who fulfill criteria for cardiac syndrome X.

Material and methods: In the current study are included 40 women with fulfilled criteria for CSX all hospitalized at the University Hospital „Alexandrovskа”, Clinic of Cardiology. Women are at the mean age of 57,73±9,5 years. All patients undergo standardized clinical examination, history of the disease was taken and 30 women were assessed by the ZUNG self-rating scale for depressive syndromes.

Кариологичният синдром X включва пациенти, основно женци, изпълняващи триадата: ангина пекторис, позитивен тест с натоварване и ангиографски коронарни артерии без промени. Клинично най-изявените симптоми при тези пациенти е гръдната болка. При повечето пациенти синдромът бъде с инвалидираща симптоматика, повишена честота на психичните заболявания и влошено качество на живот.

Цел на настоящото проучване е да се направи срезово изследване на депресивния синдром сред женци, които изпълняват критериите за кардиологичен синдром X.

Материал и методи: В настоящото проучване бяха включени 40 жени, които изпълняваха критериите за кардиологичен синдром X, които са хоспитализирани в Университетска болница „Александровска‖, Клиника по кардиология. Жените бяха средна възраст 57,73±9,5 години. Всички женци бяха преминали стандартизиран клиничен преглед, снета е анамнеза и 30 жени бяха оценени...
Results and Conclusion:
In the studied group there is a high prevalence of women in menopause and respectively the mean age is 57.73±9.52. Mean sum score from the ZSDS is 45.87±6.59 which is the score corresponding to mild depressive syndromes. Almost half of the studied women have mild depressive symptoms, one third have moderate and 10% have severe.

Depressive syndromes are usual for women with CSX and because of the prevalence of core depressive, cognitive, anxiety and somatic symptoms is very difficult to determine psychological from somatic complains in these patients.

Key words: cardiac syndrome X, depression, ZUNG scale

Cardio-vascular diseases are among the main causes for mortality and morbidity worldwide. The total social, economical and physiological burden of these diseases is growing in each developed or developing country (1,2).

In spite of the numerous studies, cardiac X syndrome (CSX) is still an undefined problem for diagnostics and treatment. This syndrome includes patients, mainly women, with the triad of angina pectoris, a positive exercise electrocardiogram for myocardial ischaemia and coronary arteries without angiographic changes. Different authors are trying to define the patogenetical mechanisms of the syndrome: myocardial ischemia, endothelial dysfunction, metabolic and hormonal factors (prevalence of women with CSX- more than 70%). The main clinical symptom in CSX is chest pain, which is usually more prolonged and difficult to treat than the typical anginal pain. Cannon et al discuss that in patients with CSX there is an impaired pain perception (3). All that heterogeneity makes the treatment approaches to those patients unclear and uncertain. This gives the right of J. C. Kaski to summarize: „Patients with CSX represent a diagnostic and therapeutic riddle“ (4). Increased number of hospitalizations of patients with CSX lead to hyperdiagnostics, including repetitive coronary angiographies with „negative“ results (more than 2 in some patients). All this is with a great burden not only for the society but also for the psychic health of each patient.

Aim of the current study is to make a cross sectional analysis of the depressive symptoms and syndrome among women who have a repetitive exertional chest pain, ECG ST-T changes and coronary arteries with no changes form angiography- fulfilling main three criteria for cardiac syndrome X.

Material and methods

In the current study are included 40 women who fulfilled criteria for CSX all hospitalized at the University Hospital „Alexandrovská“, Clinic of Cardiology. Women are at the mean age of 57.73±9.5 (ot do) years (fig1.). All patients undergo standardized clinical examina-
Mean sum score from the ZSDS is 45.87±6.59 which is the score corresponding to mild depressive syndromes (Fig.3.). Almost half of the studied women have mild depressive symptoms, one third have moderate and 10% have severe (Fig.4).

The more detailed analyses demonstrates that the higher scores are for questions 4, 5, 6, 9, 10, 13, 16 and 20th, which are respectively “I have trouble sleeping at night”, “I eat as much as I used to”, “I still enjoy sex”, “My heart beats faster than usual”, “I get tired for no reason”, “I am restless and can’t keep still”, “I find it easy to make decisions”, “I still enjoy the things I used to do”. Mean values for that questions score are respectively 2.9±0.94, 2.54±0.92, 2.76±1.0, 2.71±0.94, 3.00±0.96, 2.59±0.78, 2.48±1.09 and 3.07±0.84. After statistical analysis median score for that group of questions is 3 (Fig.5).

All this data lead to the conclusion that depressive syndrome in women with CSX could consist of core depressive, cognitive, anxiety and somatic symptoms as a result from the analysis of ZSDS.

Mean age and prevalence of menopause among the included in the study women, corresponds with data from literature for hormonal disturbance as one of the main mechanisms for

Results

In the studied group there is a high prevalence of women in menopause and respectively the mean age is 57.73±9.52 (Fig.1, 2).

<table>
<thead>
<tr>
<th>Age</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>2</td>
</tr>
<tr>
<td>50</td>
<td>6</td>
</tr>
<tr>
<td>60</td>
<td>4</td>
</tr>
<tr>
<td>70</td>
<td>2</td>
</tr>
<tr>
<td>80</td>
<td>1</td>
</tr>
</tbody>
</table>

**Figure 1.**
Distribution of patients by age.
occurrence of the CSX. First Kaski et al found that in women with CSX there is a significant lower levels of estradiol in comparison with the women from the healthy population (4).

No one of the studied patients have been ever diagnosed for depression or depressive symptoms. According to the WHO women suffer twice more often from depression than women (7). Worldwide there are more than 110 million people with depression or depressive symptoms (5). Because of the repetitive pain, often hospitalizations and a lot of instrumental examinations, some of which are painful and with a lot of risk (coronaroangiography for example), women with fulfilled criteria for CSX usually suffer from psychological diseases. Treatment of the pain syndrome is very uncertain and this is with a great burden to the quality of life of these patients. Depressive syndromes are usual for women with CSX and because of the prevalence of core depressive, cognitive, anxiety and somatic symptoms is very difficult to determine psychological from somatic complains in these patients. All that data correlates with some findings that in CSX there is impaired nervous system regulation and particularly depressed vagal tonus (6).

In conclusion, it is highly recommended to look for even mild depressive symptoms and to treat them aiming to benefit the quality of life of that women. ZUNG self-rating depression scale is well validated and easy to apply in the daily clinical practice even that of the general practitioners (8,9,10,11).
**Figure 4.** Women with mild, moderate and severe depressive symptoms according to the ZSDS sum.

**Figure 5.** Mean and median score: distribution by questions from ZSDS.
References


Address for correspondence:

Svetlin Tsonev
Medical University Sofia, „St. George Sofiiski”
Str., №1, p.c. 1431, Sofia, Bulgaria
Mobile: +359 898 426 907
E-mail: svetmed@gmail.com

Светлин Цонев
Медицински университет, София, КПБ, Клиника по кардиология, бул. „СВ. Георги Софиийски”, №1, п.к. 1431, София, Моб: +359 898 426 907 E-mail: svetmed@gmail.com
The Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is characterized by congenital absence of the upper two-third of the vagina, rudimentary cornua uteri, primary amenorrhea, and morphologically normal ovaries and Fallopian tubes due to congenital Müllerian duct total aplasia in individuals with 46, XX karyotype and female phenotype. Although the incidence of MRKH syndrome is not completely clear, there are some reports which estimate the frequency of congenital absence of vagina and rudimentary uterus as 1 in 4500 female births. Several cases of this disorder have been described in Bulgaria. The present case demonstrates a woman with diminished ovarian reserve, which is not typical characteristic of the syndrome.

We report the case of a 26-year-old nulliparous woman who was referred in our centre...
because of infertility, represented with no menstrual bleeding and unremarkable family history. The results of hormonal evaluation showed normal values of Gonadotropic hormones as well as Prolactin, Testosterone and 17β-estradiol. The main laboratory test finding was the low level of Anti-Müllerian Hormone (AMH) = \(0.47\) µg/L (NR = 1-8 µg/L), suggesting depletion of ovarian reserve. Genetic analysis showed a normal 46, XX karyotype. The definitive diagnosis of MRKH syndrome was made via laparoscopy.

This case represents type I (isolated utero-vaginal aplasia) MRKH syndrome in the absence of any other malformations such as renal, skeletal, cardiac and auditory defects. In our case a depleted ovarian capacity was observed (low AMH), which is not a typical feature of the syndrome and is in contradiction with laparoscopic evidence of the presence of follicles and Corpus Luteum. However, it is generally known that while laparoscopy and ultrasound give a snapshot of the ovaries at the day of examination, AMH reflects ovarian reserve in perspective. As far as we know this is the first case reported of MRKH syndrome in which the level of Anti-Müllerian Hormone is low.

**Key words:**
Mayer-Rokitansky-Küster-Hauser syndrome, laparoscopy, Anti-Müllerian Hormone

**Introduction**

The Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome is characterized by congenital absence of the upper two-third of the vagina, rudimentary cornua uteri, primary amenorrhea, and morphologically normal ovaries and Fallopian tubes (13, 14, 17, 19, 23) due to congenital Müllerian duct total aplasia in individuals with 46, XX karyotype and female phenotype (28).

This syndrome is subdivided in two types: the typical type I (isolated utero-vaginal aplasia) or Rokitansky sequence, and the atypical type II (incomplete aplasia and/or associated with other malformations such as renal, skeletal, cardiac and auditory defects) or MURCS association (Müllerian duct aplasia, Renal dysplasia, Cervical Somite anomalies); the frequency of type II being much greater (20, 27). Although the incidence of MRKH syndrome is not completely...
clear (12), there are some reports which estimate the frequency of congenital absence of vagina and rudimentary uterus as 1 in 4500 female births (9, 11, 30). In women presenting with primary amenorrhea, MRKH syndrome is fairly common, being second to gonadal dysgenesis as a cause of amenorrhea (7, 29). Although the pathogenesis of Müllerian aplasia associated or not with other malformations is now well-known, on the one hand, and the spectrum of malformations encountered suggests a development field defect, involving organ systems closely related during embryogenesis, on the other hand, the etiology of MRKH syndrome is still quite unclear (12, 16, 20). It was initially considered that this syndrome is of sporadic occurrence, involving some non-genetic or environmental factors (26). Now the increasing number of familial cases supports the hypothesis of a genetic cause and although the pattern of inheritance is yet undetermined, it seems to be transmitted as an autosomal dominant trait with incomplete penetrance and variable expressivity (12, 20).

Several cases of MRKH syndrome have been described in Bulgaria (1, 2, 3). A woman with this disorder has come under our observation for nearly a year. Since each case enriches the clinical picture, we considered it reasonable to describe the patient, we have observed.

**Case presentation**

P. I. V. a 26-year-old nulliparous, poorly educated woman of Bulgarian origin was referred to our center because of infertility. She had no menstrual bleeding, but she reported that every month her urine turned red, which she considered to menstrual bleeding and did not seek medical advice. She was married and had a normal sex life with normal intercourse. Her family history was unremarkable. There were no skeletal and kidney abnormalities in her family. Only her first paternal cousin was childless.

On physical examination the patient's
height was 162 cm and her weight was 50 kg (BMI 19 kg/m²). Her pulse rate was 66/min and her blood pressure was 110/60 mmHg. No skeletal abnormalities have been detected. The external examination revealed completed puberty with normal female sexual secondary development (Fig. 1). Gynecological examination found external genitalia of nulliparous, the vagina was normal, deep, ending blindly, there were no adnexa abnormalities, and Cavum Douglasi was free.

The results of hemoglobin, hematocrit, total red and white blood cells count, platelets, erythrocyte sedimentation rate (ESR), serum creatinine, serum transaminases and hemocoagulation status as well as urinalysis and sediment were normal.

Hormonal data are presented in Table 1. Gonadotropic hormones as well as Prolactin, Testosterone and 17β-estradiol were within normal limits. The key finding of these laboratory tests was the low level of Anti-Müllerian Hormone (AMH) = 0.47 µg/L (NR = 1-8 µg/L), suggesting depletion of ovarian reserve.

Genetic analysis performed on the 35 metaphase peripheral blood lymphocytes showed a normal 46, XX karyotype. An abdominal ultrasound showed normal internal organs. A thyroid ultrasound showed mild diffuse changes in the gland structure and cervical lymphadenomegaly.

Diagnostic laparoscopy revealed two rudimentary uteri – one on the right side smaller in size and the other on the left side. The left Fallopian tube, running from the left rudimentary uterus, was found to be 10-12 cm in length, normal proceeding, free of adhesions, and intact fimbriae. The right ovary was located on a typical site, with normal shape and size, free of adhesions, and the presence of follicles in various stages of development. The right Fallopian tube, running from the right rudimentary uterus, was found to be 10-11 cm in length, normal proceeding, free of adhesions, and intact fimbriae.

Table 1. Hormonal levels in the patient with MRKH syndrome

<table>
<thead>
<tr>
<th>Hormone</th>
<th>Values</th>
<th>Units</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>LH</td>
<td>2,8</td>
<td>IU/L</td>
<td>2-10</td>
</tr>
<tr>
<td>FSH</td>
<td>4,2</td>
<td>IU/L</td>
<td>1-10</td>
</tr>
<tr>
<td>Prolactin</td>
<td>460</td>
<td>mIU/L</td>
<td>&lt; 600</td>
</tr>
<tr>
<td>Testosterone</td>
<td>0,7</td>
<td>nmol/L</td>
<td>0,3-3,5</td>
</tr>
<tr>
<td>TSH</td>
<td>0,702</td>
<td>µIU/ml</td>
<td>0,27-4,2</td>
</tr>
<tr>
<td>Free T4</td>
<td>13,48</td>
<td>ng/l</td>
<td>9,3-17</td>
</tr>
<tr>
<td>Anti-Müllerian Hormone</td>
<td>↓ 0,47</td>
<td>µg/L</td>
<td>1-8</td>
</tr>
</tbody>
</table>

The right ovary was located on a typical site, with normal shape and size, free of adhesions, and the presence of Corpus Luteum. Ligamentum sacrouterina, liver, gallbladder, spleen showed no abnormalities. No surgical reconstructions had been carried out.

We also assessed her husband’s fertility by semen analysis and evaluation of his hormonal levels at the same time. The result of the semen analysis showed normozoospermia and his hormonal levels were within the normal ranges as well (FSH = 3,18 mIU/ml and Inhibin B 145 ng/l (NR = 1,5-12,4 and 120-400, respectively)) which provided evidence of preserved spermatogenic capacity.

Discussion

In this paper we describe a typical case of type I (isolated utero-vaginal aplasia) MRKH syndrome in the absence of any other malformations such as renal, skeletal, cardiac and auditory defects (20, 27) which is not the first described in Bulgaria (1, 2, 3). In the case presented, clinical suspicion of this syndrome was aroused by accident and relatively late in a prophylactic medical examination and definitively diagnosed via laparoscopy. With regard to delayed diagnosis in this case, as mentioned above, it refers to a low-educated woman, with low health literacy, who has neglected the absence of menstruation. Moreover, there is a satisfactory development of the lower segment of the vagina which allows normal sexual intercourse.
Differential diagnosis includes three conditions presenting with primary amenorrhea and normal female secondary sexual characteristics: androgen insensitivity, isolated vaginal atresia and WNT4 defects (4, 22). The most common differential diagnosis is androgen insensitivity, affected males and characterized by presence of abdominal or inguinal testes and male karyotype 46, XY (20). Another condition is isolated vaginal atresia, which occurs due to mutations in MKKS gene located on chromosome 20p12, and is found in a number of syndromes, such as Winter syndrome (involving renal, genital and middle ear malformations) and McKusick-Kaufman syndrome (involving hydrometrocolpos, postaxial polydactyly and congenital hearing malformations). Whereas the isolated vaginal atresia could be surgically corrected to make pregnancy possible, MRKH syndrome is connected with irreversible infertility (15). Finally, we should take into consideration WNT4 defects, although only two cases have been described in the literature so far. WNT4 belongs to a WNT family of genes associated with the regulation of cell and tissue growth and differentiation, and has a dominant effect. Its mutations cause a masculinization of the fetal gonads, leading to an excessive androgen production, and interfere with the primary differentiation of Müllerian ducts. Their specific clinical features are hyperandrogenism and uterine aplasia (20).

Classic clinical description of MRKH syndrome includes persons with a primary amenorrhea, normal 46, XX karyotype (5, 8, 18, 20, 24), normal ovarian function, no signs of androgen excess (10, 25), and normal secondary female sexual characteristics (20), whereas in our case a depleted ovarian capacity was observed (low AMH), in spite of the presence of follicles and Corpus Luteum. Whereas gonadal dysgenesis associated with Mayer-Rokitansky-Küster-Hauser syndrome, considered to be coincidental, has been found (6), as well as abnormally high plasma levels of AMH in patients with the same condition have been described (21); as far as we know this is the first case of MRKH syndrome in which the level of Anti-Müllerian Hormone is low. While laparoscopy and ultrasound give a snapshot of the ovaries at the day of examination, AMH reflects ovarian reserve in perspective. These data indicate that infertility is the most significant issue of the disorder and it is less likely ova from the patient for in vitro fertilization to be received. The improvement of medical technologies allows, in many countries, women to appeal for in vitro fertilization and surrogate pregnancy (4). In our case the use of donor ova should be considered.

Consent

Informed consent was obtained from the patient for publication of this case report and accompanying images at the time of the diagnosis.

References


Address for correspondence:

Rumyana Dimova, MD
Clinical Centre of Endocrinology, Medical University – Sofia, 2 Zdrave Street, Sofia 1431
e-mail: dr.rumyana.dimova@gmail.com

Д-р Румяна Димова
Клиничен център по ендокринология, МУ – София, ул. „Здраве” 2, София 1431
e-mail: dr.rumyana.dimova@gmail.com
Academician Professor Dr Samuel Refetoff, a new member of the Bulgarian Academy of Sciences and Arts

Professor Samuel Refetoff from the University of Chicago was nominated as Academician to the Bulgarian Academy of Sciences and Arts (BASA) in September 2010. The official announcement of his admission as a BASA foreign member took place in May 2011 during his visit in Sofia organized by the Bulgarian Fulbright Commission for educational exchange.

Professor Samuel Refetoff was born on July 11, 1937, in one of the most cultural centers of Bulgaria, the city of Russe. His education and postgraduate training in medicine has been held in universities of Montreal (Canada), Los Angelis and Boston (USA). The academic career of Prof. Refetoff started in Harvard Medical School in 1968 following the University of Chicago where he was elected as professor of medicine (1977), later as professor of pediatrics. Since 2001 he has been professor in the Committees on Genetics and Molecular Medicine, Director of the endocrinology training program to the same university.

Prof. S. Refetoff is prize-winner of many awards as well as honorary degrees. His professional memberships include more than 15 medical associations and institutes in the USA and Europe. He is also a member of many scientific journals, including „Bulgarian Medicine“ (BASA) and „Endocrinologia“ (Edition of the Bulgarian Society of Endocrinology).

The research of Prof. S. Refetoff has been funded without interruption since 1971 up to date mainly by the National Institutions of Health (USA) as well as the University of Chicago. He discovered the inherited syndrome of resistance to thyroid hormone („Refetoff Syndrome“) and elucidated its genetic and molecular base. This was the subject of his plenary lecture at the Scientific Meeting organized by BASA on May 19, 2011 in Sofia. In the same event he was congratulated by the Academy President, Academician Prof. Dr. Grigor Velev who gave him the acknowledgement as an outstanding foreign member of BASA. He also expressed the highest appreciation for the world-recognized contributions of Professor Samuel Refetoff in fundamental and clinical endocrinology.
One anniversary – two heroes

This year Academician Prof. Dr Miladin Apostolov, and the foreign BASA member Academician Prof. Dr Spiros Marketos, both born in 1931, are getting on for the dignity age of 80! Both of them are historians of Medicine and are doyens of the History and Philosophy of Medicine in Bulgaria and in Greece. Both of them are supporters of the idea for the unification of the Balkan historians of Medicine.

They share in Hippokrates’ philosophy by teaching Hippokratism and Neohippokratism. They both are pillars of the historic-medical science in Bulgaria and in Greece, in the Balkan Peninsula and in Europe.

The irksome biographical data describe – individually or in common – their rich professional, scientific, intellectual, teacher’s and publication activities.

Prof. Miladin Apostolov comes from the village Komoshitza, near Lom town, Bulgaria, and Prof. Spiros Marketos – from Athens, Greece. But both of them have graduated Medicine – the science that gives knowledge about human beings at the most - and they elicit from the profundity of the civilization and to nowadays the development of Medicine and its prominent creators in their historical, philosophic, social and ethical aspects. Prof. M. Apostolov is more socially engaged, while Prof. Sp. Marketos is mostly a theoretician.

The philosophy roots and humanistic sources of Hippokratic medicine are among the favourite research topics of Prof. Marketos – he has a lot of publications and congress reports about Medicine as science and art in Ancient Greece, on Hippokratic ethics in modern medicine, that historically and culturally reveals how necessary it is for the overcoming the biomedical problems of today’s medicine, etc. Some of his recent books are Hellenic Medicine (1991), History

As a scientist of dynamic nature Prof. Apostolov has organized several international scientific expeditions on History of Medicine – Hippokrates (Kos island, 1972), Ioan Petriciy (Tbilisi, Baku, Yerevan, 1983), Amatus Lusitanus (Spain, Portugal, 1986), and in Bulgaria – Pavlikeny town, Kabile-Yambol, Varna, etc. Prof. M. Apostolov is the „father“ of some awards – Golden Hippokrates – for excellent mark and scientific research of medical students; Purple Heart – for mercy and charity; BAHPM’s Golden Hippokratic Oath – for high professionalism in medicine and Hippokratic attitude to the patients.

Prof. Miladin Apostolov is president of the Bulgarian society of history of medicine (since 1983), Honorary member and Doctor Honoris Causa of Panhellenic society of history of medicine; member-academician of BASA and its vice-president; Honorary academician at the Petrovskaya academy of sciences and arts (PASA); Honorary member of the Panhellenic association on history,
Clinical Toxicology in Bulgaria
Клинична токсикология в България. ABCT, София, 2010.

The Bulgarian Clinical Toxicology Association issued a collection of articles on the development of the Clinical toxicology in Bulgaria, founded as a separate medical discipline in 1963. The articles cover the civil and military Clinical toxicology net in Bulgaria – N. I. Pirogov University Hospital and Military medical academy (Sofia), the toxicology clinics in Plovdiv and Pleven, Naval hospital (Varna) and the regional centre for acute intoxications (Dobrich).

Assoc. Prof. and BASA member-observer Dr Eugenia Barzashka describes the short history of the Clinical toxicology care in Pleven region. A sector has been established in 1990, and a ward – in 1995. At present the pediatric sector operates with 5 beds, and this one for the adults – with 10 beds. The activities of the oldest clinical toxicology unit in Bulgaria is presented historically and in detail by Assoc. Prof. and BASA correspond-

10 Principles of the Medic and the Manager

The Bulgarian Clinical Toxicology Association issued a collection of articles on the development of the Clinical toxicology in Bulgaria, founded as a separate medical discipline in 1963. The articles cover the civil and military Clinical toxicology net in Bulgaria – N. I. Pirogov University Hospital and Military medical academy (Sofia), the toxicology clinics in Plovdiv and Pleven, Naval hospital (Varna) and the regional centre for acute intoxications (Dobrich).

Assoc. Prof. and BASA member-observer Dr Eugenia Barzashka describes the short history of the Clinical toxicology care in Pleven region. A sector has been established in 1990, and a ward – in 1995. At present the pediatric sector operates with 5 beds, and this one for the adults – with 10 beds. The activities of the oldest clinical toxicology unit in Bulgaria is presented historically and in detail by Assoc. Prof. and BASA correspond-

Thank you, congratulations and be healthy, dear Professors!!!

Assoc. Prof. Dr Marussya Petkova, MD, PhD Bulgarian Academy of Sciences and Arts (BASA) – Sofia
The author is well known as a scientist, teacher, manager and creator among the medical community. After decades of gaining experience and knowledge, broadening of philosophic, ethic, cultural and professional outlook and ideas, efforts for intellectual self-perfection, it comes the time to take the pencil and to lay down on the white sheet the clarified cogitations. In his last book Prof. Dr Tzekomir Vodenicharov - academician at BASA - shows his ten principles, leading to success and recommends them to the medical doctors and health managers: Have an immortal aim; Don't believe, but analyse; Think associatively and integrally; Follow the great, but take care for the details; Be useful; Plan out; Forecast; Organize; Dream; Act. Principle by principle he describes the mode of behaviour to reach the wanted level of professional, managerial and material success. To illustrate his recommendations Prof. Vodenicharov uses a lot of examples, coming from history, philosophy, world literature, culture and his own life. In unison with the philosophic character of the text the somehow abstract illustrations, made by Anatoly Alexiev, follow its intellectual ringing. The narration is interesting, the book is written in nice and rich Bulgarian language and really it's pleasure to read it.

Looking for the balance in our life, let us follow Prof. Vodenicharov's testaments: Be person of yourself, Share your knowledge to reach immortality.

Assoc. Prof. Dr Marussya Petkova, MD, PhD
Bulgarian Academy of Sciences and Arts (BASA) - Sofia

Last goodbye to Academician Dr Peter Konstantinov

On 12th of June 2011, as a result of a painful illness Prof. Dr Peter Konstantinov – full member of BASA, sharing its ideas, mission and activities, patriot, zealot for everything Bulgarian, distinguished intellectual and prominent public personality, passed away.

Peter Konstantinov Stoyanov was born on 01.08.1929 in the town of Kazanluk. He was master in Medicine (1952) and Political economy (1966), and specialist in Internal Medicine, Cardiology and Rheumatology. He is the author of more than 140 scientific publications and had active medical practice for 45 years. But the Bulgarian communities all over the world knew Dr Konstantinov mainly as an interesting writer, novelist and publicist, and as a socially active person – one of the founders and president since 1989 of the National association „Mati Bolgaria“ - the first independent organization in Bulgaria after 1989, that, thanks to Dr Konstantinov, worked intensively for saving of the Bulgarian traditions, culture and historical memory among the Bulgarians all over the world.

As a publicist in the field of Political economy Dr Konstantinov wrote the books „History of Bulgaria with her concealed historical facts“, „For and against the Bulgaria national interests“, „Social and economic problems of the sciento-technical revolution“, etc. For the lovers of literature and art, prof. Konstantinov is a remarkable narrator and eloquent writer, prominent intellectual with mighty Renaissance spirit. An ardent admirer of fine arts he wrote some art itinerary books – „The treasures of the world“, „The treasures of Europe“, „The treasures of Bulgaria“, etc. All his works are written in vivid, beautiful and rich Bulgarian language.

Besides, in 1985 he endowed the town „Iskra“ library in Kazanluk with 1023 volumes of fiction and reference books, and some years later he gifted 100 canvases by distinguished Bulgarian artists of his own to the Kazanluk Picture-gallery.

For his literary creation Dr Peter Konstantinov received two significant awards – the „Dimitar Dimov“ literature prize, given to physicians (2006) and in 2009 he was elected as Honorary Citizen of Kazanluk town.

Deep obeisance to his luminous memory and may his spirit live and rest in peace for ever!

Editorial Board of Bulgarian medicine journal
The Bulgarian Medicine Journal, official edition of the Bulgarian Academy of Science and Arts, Science Division, Research Center for Medicine and Health Care is published in 4 issues per year. It accepts for publication reviews, original research articles, case reports, short communications, opinions on new medical books, letters to the editor and announcements for scientific events (congresses, symposia, etc) in all fields of fundamental and clinical medicine. The journal is published in English with exceptional reviews on significant topics in Bulgarian. The detailed abstracts and the titles of the articles, the names of the authors and institutions as well as the legends of the illustrations (figures and tables) are printed in Bulgarian and English.

The manuscripts should be submitted in two printed copies, on standard A4 sheets (21/30 cm), double spaced, 60 characters per line, and 30 lines per standard page.

The size of each paper should not exceed 10 pages (up to 5 000 words) for original research articles, 12 pages for reviews (7 500 words), up to 4 pages for case reports, 2 pages for short communications, 4 pages for discussions or correspondence on scientific events or medical books. The references and illustrations are included in this size (two 9x13 cm figures, photographs, tables or diagrams are considered as one standard page).

The abstracts are not included in the size of the paper and should be submitted on a separate page with 3 to 5 key words at the end of the abstract. They should reflect the most essential topics of the article, including the objectives and hypothesis of the research work, the procedures, the main findings and the principal conclusions. The abstracts should not exceed one standard typewritten page of 200 words.

The basic structure of the manuscripts should meet the following requirements:

**Title page**

The title of the article, forename, middle initials (if any) and family name of each author; institutional affiliation; name of department(s) and institutions to which the work should be attributed, address and fax number of the corresponding author.

**Text of the article**

The original research reports should have the following structure: introduction (states the aim, summarizer the rationale for the study), subjects and materials, methods (procedure and apparatus in sufficient detail, statistical methods), results, discussion, conclusions (should be linked with the aims of the study, but unqualified statements not completely supported by research data should be avoided). These requirements are not valid for the other types of manuscripts. Only officially recognized abbreviations should be used, all others should be explained in the text. Units should be used according to the International System of Units (S. I. units). Numbers to bibliographical references should be used according to their enumeration in the reference list.

**Illustrations**

The figures, diagrams, schemes, photos should be submitted in a separate file with: consecutive number (in Arabic figures); titles of the article and name of the first author. The explanatory text accompanying the figures should be presented along with the respective number of the figure in the main text body with space left for insertion of the figure.

**References**

The references should be presented on a separate page at the end of the manuscript. It is recommended that the number of references should not Exceed 20 titles for the original articles and 40 titles for the reviews; 70% of them should be published in the last 5 years. References should be listed in alphabetical order, English first, followed by the Bulgarian ones in the respective alphabetic order. The number of the reference should be followed by the family name of the first author and then his/her initials, names of the second and other authors should start with the initials followed by the family names. The full title of the cited article should be written, followed by the name of the journal where it has been published (or its generally accepted abbreviation), volume, year, issue, first and last page. Chapters of books should be cited in the same way, the full name off the chapter first, followed by “In:” full title of the book, editors, publisher, town, year, first and final page number of the cited chapter.

**Examples:**

Reference to a journal article:


Reference to a book chapter:


Submission of manuscripts

The original and one copy of the complete manuscript are submitted together with a covering letter granting
Author's guidelines

the consent of all authors for the publication of the article as well as a statement that it has not been published previously elsewhere and signed by the first author. The procedure should be complemented via electronic submission. Manuscripts of articles accepted for publication will not be returned to the authors.

Peer-review process: following the international standards in the field, the Editorial board has adopted double-blind peer-review policy assigned to independent referees. Following acceptance for publication the authors are charged 5 euros per page.

Ethical regulations: reports with experiments on human subjects should specify whether the procedures were conducted in accordance with the ethical norms if the responsible committee on Human experimentation (local or regional) and/or with the Helsinki Declaration, as revised in 2000. Respective guidelines for animal experimentation should be considered.

Address for sending of manuscripts and other editorial correspondence

Prof. Dr Philip Kumanov Editor-in-chief, University Hospital of Endocrinology, 1431 Sofia, Zdrave str. 2, or electronic address: phkumanov@lycos.com

With copy for the scientific secretary – Assoc. Prof. Drozdstoj Stoyanov: stojanovpisevski@gmail.com

Изисквания към авторите

Списание „Българска медицина“, издане на Българската Академия на Науките и Изкуствата, Отделение за наука, Научен Център по Медицина и Здравеопазване излиза в четири книжки годишно. В него се отпечатват оригинални научни статии, казуистични съобщения, обзори, рецензии и съобщения за състоянието на клиничната и фундаменталната медицина. Списаниеето излиза на английски език с подробни резюмета на български и английски. Изключено се превежда за обзорни статии по особено значими теми. Заглавията, авторските колективи, а също националните и международните списания на илюстрациите и в таблиците се отпечатват на двете езици. Материалите, предоставени от чужди автори се помещават на английски с подробно резюме на български.

Материалите трябва да се предоставят в два еднаквия печатни екземпляра на хартия формат A4 (21 х 30 см), 30 реда с 60 знака на ред при двоен интервал между редове (стандартна машинописна страница). Оформени така, материалите могат да бъдат изпратени като прикачени файлове по электронна поща на адреса, посочен по-долу.

Обемът на представените работи не трябва да превишива 10 стандартни страници за оригиналните статии (или 5000 думи), 12 страници (7500 думи) – за обзорните статии, 3-4 страници за казуистичните съобщения, 4 страници за информация относно научни праеви в България и в чужбина, както и за научни дискусии, 2 страници за рецензии на книги (монографии и учебници). В посочения обем се включват книжописи и всички илюстрации и таблици. В същност не се включват резюметата на български и английски, чиято обем трябва да бъде не повече от 200 думи за всяко (25-30 машинописни реда). Резюметата се предоставят на отделна страница. Те трябва да отразяват конкретно работната хипотеза и целта на разработката, използваните методи, най-важните резултати и заключения. Ключовите думи (до 5), съобразени с „Medline“, трябва да се посочат в края на всяко резюме.

Структурата на статиите трябва да отговаря на следните изисквания:

Титула страница

а) заглавие, имена на авторите (собствено име и фамилия), название на научната организация или лечебното заведение, в което те работят. При повече от едно заведение името на съответните автори се маркират с цифри или звездички;

б) същите данни на английски език се изписват пред българския текст.

Забеляжка: при статии от чужди автори българският текст следва английския.

Основен текст на статията

Оригиналните статии запължително трябва да имат следната структура: увод, материали и методи, собствени резултати, обсъждане, заключение и извод.

Методиките трябва да бъдат подробно описани (включително видът и фирмата произвеждач на използваните реактиви и апаратура). Същото се отнася и за статистическите методи.
Илустративи и таблици

Илюстративите към текста (с необходимия добър контраст и качество), се предлагат на отделни листове (без обяснителен текст), в оригинален е и две копии за всяка от тях. Текстът към фигурите със съответната им номинация (на български и на английски език) се отбелязва в текста. Основното текстуално тяло на статията под съответния номер на мястото, където трябва да се разположи при предпечатната подготовка. Таблиците се предлагат с готово написано обяснително текстова описание на български и на английски, които са разположени над тях; номинацията им е отделена (също с арабски цифри).

Използвана литература:

Книгописът се предлага на отделна страна. Боят на цитираните източници е препоръчително да не надхвърля 20 (за обзорите до 40), като желателно е ловечето от тях да бъдат от последните 5 години. Подраждането става по азбучен ред на фамилното име на първия автор (тържестно на кирилица, после на латиница), като след поредния номер се отбелязва фамилното име на първия автор, след това инициалите му; всички останали автори се посочват с инициалите, последвани от фамилното име (в обратен ред) до третия автор, последуван от съкрашението et al. Следва цялото заглавие на цитираната статия, след него – названията на списанието (или общоприетото му съкрашение), том, година, евентуално брой на книжката, началната и крайната страна. Глави (разделу) от книги се изписват по аналогичен начин, като след автора и заглавието на главата (раздела) се отбелязва пълното заглавие на книгата, наименования на редакторите (в скоби), издателство, градът и годината на издаване, началната и крайната страница на раздела.

Процедура по рецензията:

С оглед спазване на международните стандарти, редакционната колегия е приемала процедура по „двойно сляпо“ рецензия от независими референти. След положителна рецензия и одобрение от редколегията авторите на статията дължат заплащане в размер на 10 лв. за всяка страница.

Етически съображения: всички трудове, които отразяват експерименти с хора следва да бъдат съобразени с етическите норми и регуляции, въведени от съответния научен институт или регионална научна комисия и/или с Декларацията от Хелзинки, ревизия от 2000г. Експериментите с животни следва да бъдат също така съобразени със съответните норми и правила.

Всички материали за списанието се изразигат на адрес на редакцията:

Проф. Др. Филип Куманов, Университетска болница по Ендокринология, 1431 София, ул. Здраве 2, Или по електронен път на адрес: phkumanov@lycos.com

С копие до научния секретар– Доц. Др Дроздстой Стоянов: stojanovpisevski@gmail.com
Bulgarian medicine

Journal of Bulgarian Academy of Sciences and Arts

Founding Editor
Prof. Dr Grigor VELEV

Philip KUMANOV, Editor-in-chief
Филип Куманов (главен редактор)
phkumanov@lycos.com

Drozdstoj Stoyanov, Scientific Secretary
Дроздстой Стоянов, научен секретар
stojanovpisevski@gmail.com

Drozdstoj Stoyanov, English editor
Дроздстой Стоянов, редактор на английски език

© Cover&Design, R&S
© Първа корица и графичен дизайн, R&S

Stefan Ninov, prepress
Стефан Нинов, предпечат
stefanninov@gmail.com

Изданието се разпространява безплатно
Тираж 2 500

ISSN 1314-3387

Списание на
Българска Академия на
Науките и Изкуствата

Основател и първи главен редактор
проф. д-р Григор ВЕЛЕВ, д.м.н.